ID   SIR1_HUMAN              Reviewed;         747 AA.
AC   Q96EB6; Q2XNF6; Q5JVQ0; Q9GZR9; Q9Y6F0;
DT   31-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   31-OCT-2003, sequence version 2.
DT   18-JUN-2025, entry version 223.
DE   RecName: Full=NAD-dependent protein deacetylase sirtuin-1 {ECO:0000305};
DE            Short=hSIRT1;
DE            EC=2.3.1.286 {ECO:0000255|PROSITE-ProRule:PRU00236, ECO:0000269|PubMed:12006491, ECO:0000269|PubMed:22918831, ECO:0000269|PubMed:30409912, ECO:0000269|PubMed:32034146};
DE   AltName: Full=NAD-dependent protein deacylase sirtuin-1 {ECO:0000305};
DE            EC=2.3.1.- {ECO:0000269|PubMed:28497810};
DE   AltName: Full=Regulatory protein SIR2 homolog 1;
DE   AltName: Full=SIR2-like protein 1;
DE            Short=hSIR2;
DE   Contains:
DE     RecName: Full=SirtT1 75 kDa fragment {ECO:0000303|PubMed:21987377};
DE              Short=75SirT1 {ECO:0000303|PubMed:21987377};
GN   Name=SIRT1 {ECO:0000303|PubMed:12535671, ECO:0000312|HGNC:HGNC:14929};
GN   Synonyms=SIR2L1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Testis;
RX   PubMed=10381378; DOI=10.1006/bbrc.1999.0897;
RA   Frye R.A.;
RT   "Characterization of five human cDNAs with homology to the yeast SIR2 gene:
RT   Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-
RT   ribosyltransferase activity.";
RL   Biochem. Biophys. Res. Commun. 260:273-279(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH HES1 AND HEY2,
RP   MUTAGENESIS OF HIS-363, AND ACTIVE SITE.
RX   PubMed=12535671; DOI=10.1016/s0006-291x(02)03020-6;
RA   Takata T., Ishikawa F.;
RT   "Human Sir2-related protein SIRT1 associates with the bHLH repressors HES1
RT   and HEY2 and is involved in HES1- and HEY2-mediated transcriptional
RT   repression.";
RL   Biochem. Biophys. Res. Commun. 301:250-257(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLU-3.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 124-747.
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION IN DEACETYLATION OF TP53, SUBCELLULAR LOCATION, MUTAGENESIS OF
RP   HIS-363, AND ACTIVE SITE.
RX   PubMed=11672523; DOI=10.1016/s0092-8674(01)00527-x;
RA   Vaziri H., Dessain S.K., Ng Eaton E., Imai S., Frye R.A., Pandita T.K.,
RA   Guarente L., Weinberg R.A.;
RT   "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.";
RL   Cell 107:149-159(2001).
RN   [7]
RP   FUNCTION, ENZYME ACTIVITY, SUBCELLULAR LOCATION, INTERACTION WITH PML,
RP   MUTAGENESIS OF HIS-363, AND ACTIVE SITE.
RX   PubMed=12006491; DOI=10.1093/emboj/21.10.2383;
RA   Langley E., Pearson M., Faretta M., Bauer U.-M., Frye R.A., Minucci S.,
RA   Pelicci P.G., Kouzarides T.;
RT   "Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular
RT   senescence.";
RL   EMBO J. 21:2383-2396(2002).
RN   [8]
RP   ACTIVITY REGULATION.
RX   PubMed=12297502; DOI=10.1074/jbc.m205670200;
RA   Bitterman K.J., Anderson R.M., Cohen H.Y., Latorre-Esteves M.,
RA   Sinclair D.A.;
RT   "Inhibition of silencing and accelerated aging by nicotinamide, a putative
RT   negative regulator of yeast sir2 and human SIRT1.";
RL   J. Biol. Chem. 277:45099-45107(2002).
RN   [9]
RP   ACTIVITY REGULATION.
RX   PubMed=12939617; DOI=10.1038/nature01960;
RA   Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G.,
RA   Zipkin R.E., Chung P., Kisielewski A., Zhang L.-L., Scherer B.,
RA   Sinclair D.A.;
RT   "Small molecule activators of sirtuins extend Saccharomyces cerevisiae
RT   lifespan.";
RL   Nature 425:191-196(2003).
RN   [10]
RP   FUNCTION.
RX   PubMed=15152190; DOI=10.1038/sj.emboj.7600244;
RA   Frye R.A., Mayo M.W.;
RT   "Modulation of NF-kappaB-dependent transcription and cell survival by the
RT   SIRT1 deacetylase.";
RL   EMBO J. 23:2369-2380(2004).
RN   [11]
RP   FUNCTION IN DEACETYLATION OF FOXO3, AND FUNCTION IN REGULATION OF FOXO3.
RX   PubMed=14980222; DOI=10.1016/s0092-8674(04)00126-6;
RA   Motta M.C., Divecha N., Lemieux M., Kamel C., Chen D., Gu W., Bultsma Y.,
RA   McBurney M., Guarente L.;
RT   "Mammalian SIRT1 represses forkhead transcription factors.";
RL   Cell 116:551-563(2004).
RN   [12]
RP   FUNCTION IN DEACETYLATION OF MLLT7.
RX   PubMed=15126506; DOI=10.1074/jbc.m401138200;
RA   van der Horst A., Tertoolen L.G.J., de Vries-Smits L.M.M., Frye R.A.,
RA   Medema R.H., Burgering B.M.T.;
RT   "FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity
RT   protein hSir2(SIRT1).";
RL   J. Biol. Chem. 279:28873-28879(2004).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15469825; DOI=10.1016/j.molcel.2004.08.031;
RA   Vaquero A., Scher M., Lee D., Erdjument-Bromage H., Tempst P., Reinberg D.;
RT   "Human SirT1 interacts with histone H1 and promotes formation of
RT   facultative heterochromatin.";
RL   Mol. Cell 16:93-105(2004).
RN   [14]
RP   FUNCTION IN DEACETYLATION OF FOXO3, AND FUNCTION IN REGULATION OF FOXO3.
RX   PubMed=14976264; DOI=10.1126/science.1094637;
RA   Brunet A., Sweeney L.B., Sturgill J.F., Chua K.F., Greer P.L., Lin Y.,
RA   Tran H., Ross S.E., Mostoslavsky R., Cohen H.Y., Hu L.S., Cheng H.L.,
RA   Jedrychowski M.P., Gygi S.P., Sinclair D.A., Alt F.W., Greenberg M.E.;
RT   "Stress-dependent regulation of FOXO transcription factors by the SIRT1
RT   deacetylase.";
RL   Science 303:2011-2015(2004).
RN   [15]
RP   FUNCTION IN DEACETYLATION OF XRCC6, AND INDUCTION BY CR.
RX   PubMed=15205477; DOI=10.1126/science.1099196;
RA   Cohen H.Y., Miller C., Bitterman K.J., Wall N.R., Hekking B., Kessler B.,
RA   Howitz K.T., Gorospe M., de Cabo R., Sinclair D.A.;
RT   "Calorie restriction promotes mammalian cell survival by inducing the SIRT1
RT   deacetylase.";
RL   Science 305:390-392(2004).
RN   [16]
RP   INTERACTION WITH FHL2, FUNCTION IN DEACETYLATION OF FOXO1, AND FUNCTION IN
RP   REGULATION OF FOXO1.
RX   PubMed=15692560; DOI=10.1038/sj.emboj.7600570;
RA   Yang Y., Hou H., Haller E.M., Nicosia S.V., Bai W.;
RT   "Suppression of FOXO1 activity by FHL2 through SIRT1-mediated
RT   deacetylation.";
RL   EMBO J. 24:1021-1032(2005).
RN   [17]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16079181; DOI=10.1091/mbc.e05-01-0033;
RA   Michishita E., Park J.Y., Burneskis J.M., Barrett J.C., Horikawa I.;
RT   "Evolutionarily conserved and nonconserved cellular localizations and
RT   functions of human SIRT proteins.";
RL   Mol. Biol. Cell 16:4623-4635(2005).
RN   [18]
RP   FUNCTION IN DEACETYLATION OF MEF2D, AND INTERACTION WITH HDAC4.
RX   PubMed=16166628; DOI=10.1128/mcb.25.19.8456-8464.2005;
RA   Zhao X., Sternsdorf T., Bolger T.A., Evans R.M., Yao T.-P.;
RT   "Regulation of MEF2 by histone deacetylase 4- and SIRT1 deacetylase-
RT   mediated lysine modifications.";
RL   Mol. Cell. Biol. 25:8456-8464(2005).
RN   [19]
RP   INTERACTION WITH HIV-1 TAT (MICROBIAL INFECTION).
RX   PubMed=15719057; DOI=10.1371/journal.pbio.0030041;
RA   Pagans S., Pedal A., North B.J., Kaehlcke K., Marshall B.L., Dorr A.,
RA   Hetzer-Egger C., Henklein P., Frye R., McBurney M.W., Hruby H., Jung M.,
RA   Verdin E., Ott M.;
RT   "SIRT1 regulates HIV transcription via Tat deacetylation.";
RL   PLoS Biol. 3:210-220(2005).
RN   [20]
RP   ASSOCIATION WITH THE PRC4 COMPLEX, AND INTERACTION WITH SUZ12.
RX   PubMed=15684044; DOI=10.1073/pnas.0409875102;
RA   Kuzmichev A., Margueron R., Vaquero A., Preissner T.S., Scher M.,
RA   Kirmizis A., Ouyang X., Brockdorff N., Abate-Shen C., Farnham P.J.,
RA   Reinberg D.;
RT   "Composition and histone substrates of polycomb repressive group complexes
RT   change during cellular differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:1859-1864(2005).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-47, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH E2F1.
RX   PubMed=16892051; DOI=10.1038/ncb1468;
RA   Wang C., Chen L., Hou X., Li Z., Kabra N., Ma Y., Nemoto S., Finkel T.,
RA   Gu W., Cress W.D., Chen J.;
RT   "Interactions between E2F1 and SirT1 regulate apoptotic response to DNA
RT   damage.";
RL   Nat. Cell Biol. 8:1025-1031(2006).
RN   [23]
RP   FUNCTION IN DEACETYLATION OF RB1.
RX   PubMed=17620057; DOI=10.1042/bj20070151;
RA   Wong S., Weber J.D.;
RT   "Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1.";
RL   Biochem. J. 407:451-460(2007).
RN   [24]
RP   INTERACTION WITH TLE1.
RX   PubMed=17680780; DOI=10.1042/bj20070817;
RA   Ghosh H.S., Spencer J.V., Ng B., McBurney M.W., Robbins P.D.;
RT   "Sirt1 interacts with transducin-like enhancer of split-1 to inhibit
RT   nuclear factor kappaB-mediated transcription.";
RL   Biochem. J. 408:105-111(2007).
RN   [25]
RP   FUNCTION, MUTAGENESIS OF HIS-363, AND ACTIVE SITE.
RX   PubMed=17290224; DOI=10.1038/sj.emboj.7601563;
RA   Pedersen T.A., Bereshchenko O., Garcia-Silva S., Ermakova O., Kurz E.,
RA   Mandrup S., Porse B.T., Nerlov C.;
RT   "Distinct C/EBPalpha motifs regulate lipogenic and gluconeogenic gene
RT   expression in vivo.";
RL   EMBO J. 26:1081-1093(2007).
RN   [26]
RP   FUNCTION IN DEACETYLATION OF XRCC6, AND FUNCTION IN DNA REPAIR.
RX   PubMed=17334224; DOI=10.1038/emm.2007.2;
RA   Jeong J., Juhn K., Lee H., Kim S.H., Min B.H., Lee K.M., Cho M.H.,
RA   Park G.H., Lee K.H.;
RT   "SIRT1 promotes DNA repair activity and deacetylation of Ku70.";
RL   Exp. Mol. Med. 39:8-13(2007).
RN   [27]
RP   FUNCTION IN DEACETYLATION OF TP73, AND FUNCTION IN REGULATION OF TP73.
RX   PubMed=16998810; DOI=10.1002/jcp.20831;
RA   Dai J.M., Wang Z.Y., Sun D.C., Lin R.X., Wang S.Q.;
RT   "SIRT1 interacts with p73 and suppresses p73-dependent transcriptional
RT   activity.";
RL   J. Cell. Physiol. 210:161-166(2007).
RN   [28]
RP   FUNCTION IN AR-DEPENDENT REPRESSION.
RX   PubMed=17505061; DOI=10.1210/me.2006-0467;
RA   Dai Y., Ngo D., Forman L.W., Qin D.C., Jacob J., Faller D.V.;
RT   "Sirtuin 1 is required for antagonist-induced transcriptional repression of
RT   androgen-responsive genes by the androgen receptor.";
RL   Mol. Endocrinol. 21:1807-1821(2007).
RN   [29]
RP   INTERACTION WITH RPS19BP1.
RX   PubMed=17964266; DOI=10.1016/j.molcel.2007.08.030;
RA   Kim E.-J., Kho J.-H., Kang M.-R., Um S.-J.;
RT   "Active regulator of SIRT1 cooperates with SIRT1 and facilitates
RT   suppression of p53 activity.";
RL   Mol. Cell 28:277-290(2007).
RN   [30]
RP   ERRATUM OF PUBMED:17964266.
RA   Kim E.-J., Kho J.-H., Kang M.-R., Um S.-J.;
RL   Mol. Cell 28:513-513(2007).
RN   [31]
RP   FUNCTION IN DEACETYLATION OF NR1H3 AND NR1H2.
RX   PubMed=17936707; DOI=10.1016/j.molcel.2007.07.032;
RA   Li X., Zhang S., Blander G., Tse J.G., Krieger M., Guarente L.;
RT   "SIRT1 deacetylates and positively regulates the nuclear receptor LXR.";
RL   Mol. Cell 28:91-106(2007).
RN   [32]
RP   FUNCTION IN DEACETYLATION OF NBN, AND FUNCTION IN DNA REPAIR.
RX   PubMed=17612497; DOI=10.1016/j.molcel.2007.05.029;
RA   Yuan Z., Zhang X., Sengupta N., Lane W.S., Seto E.;
RT   "SIRT1 regulates the function of the Nijmegen breakage syndrome protein.";
RL   Mol. Cell 27:149-162(2007).
RN   [33]
RP   FUNCTION IN DEACETYLATION OF HIC1.
RX   PubMed=17283066; DOI=10.1128/mcb.01098-06;
RA   Stankovic-Valentin N., Deltour S., Seeler J., Pinte S., Vergoten G.,
RA   Guerardel C., Dejean A., Leprince D.;
RT   "An acetylation/deacetylation-SUMOylation switch through a phylogenetically
RT   conserved psiKXEP motif in the tumor suppressor HIC1 regulates
RT   transcriptional repression activity.";
RL   Mol. Cell. Biol. 27:2661-2675(2007).
RN   [34]
RP   FUNCTION, MUTAGENESIS OF HIS-363, AND ACTIVE SITE.
RX   PubMed=18004385; DOI=10.1038/nature06268;
RA   Vaquero A., Scher M., Erdjument-Bromage H., Tempst P., Serrano L.,
RA   Reinberg D.;
RT   "SIRT1 regulates the histone methyl-transferase SUV39H1 during
RT   heterochromatin formation.";
RL   Nature 450:440-444(2007).
RN   [35]
RP   FUNCTION.
RX   PubMed=18662546; DOI=10.1016/j.cell.2008.06.050;
RA   Asher G., Gatfield D., Stratmann M., Reinke H., Dibner C., Kreppel F.,
RA   Mostoslavsky R., Alt F.W., Schibler U.;
RT   "SIRT1 regulates circadian clock gene expression through PER2
RT   deacetylation.";
RL   Cell 134:317-328(2008).
RN   [36]
RP   IDENTIFICATION IN THE ENOSC COMPLEX, FUNCTION, MUTAGENESIS OF HIS-363, AND
RP   ACTIVE SITE.
RX   PubMed=18485871; DOI=10.1016/j.cell.2008.03.030;
RA   Murayama A., Ohmori K., Fujimura A., Minami H., Yasuzawa-Tanaka K.,
RA   Kuroda T., Oie S., Daitoku H., Okuwaki M., Nagata K., Fukamizu A.,
RA   Kimura K., Shimizu T., Yanagisawa J.;
RT   "Epigenetic control of rDNA loci in response to intracellular energy
RT   status.";
RL   Cell 133:627-639(2008).
RN   [37]
RP   PHOSPHORYLATION AT SER-27 AND SER-47.
RX   PubMed=18838864; DOI=10.4161/cc.7.19.6799;
RA   Ford J., Ahmed S., Allison S., Jiang M., Milner J.;
RT   "JNK2-dependent regulation of SIRT1 protein stability.";
RL   Cell Cycle 7:3091-3097(2008).
RN   [38]
RP   INTERACTION WITH HIV-1 TAT (MICROBIAL INFECTION), AND FUNCTION IN T-CELL
RP   ACTIVATION (MICROBIAL INFECTION).
RX   PubMed=18329615; DOI=10.1016/j.chom.2008.02.002;
RA   Kwon H.S., Brent M.M., Getachew R., Jayakumar P., Chen L.F., Schnolzer M.,
RA   McBurney M.W., Marmorstein R., Greene W.C., Ott M.;
RT   "Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1
RT   deacetylase and induces T cell hyperactivation.";
RL   Cell Host Microbe 3:158-167(2008).
RN   [39]
RP   FUNCTION IN DEACETYLATION OF WRN, AND FUNCTION IN DNA DAMAGE.
RX   PubMed=18203716; DOI=10.1074/jbc.m709707200;
RA   Li K., Casta A., Wang R., Lozada E., Fan W., Kane S., Ge Q., Gu W.,
RA   Orren D., Luo J.;
RT   "Regulation of WRN protein cellular localization and enzymatic activities
RT   by SIRT1-mediated deacetylation.";
RL   J. Biol. Chem. 283:7590-7598(2008).
RN   [40]
RP   FUNCTION IN DEACETYLATION OF STK11.
RX   PubMed=18687677; DOI=10.1074/jbc.m805711200;
RA   Lan F., Cacicedo J.M., Ruderman N., Ido Y.;
RT   "SIRT1 modulation of the acetylation status, cytosolic localization, and
RT   activity of LKB1. Possible role in AMP-activated protein kinase
RT   activation.";
RL   J. Biol. Chem. 283:27628-27635(2008).
RN   [41]
RP   INTERACTION WITH CCAR2, ACTIVITY REGULATION, MUTAGENESIS OF HIS-363, ACTIVE
RP   SITE, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=18235501; DOI=10.1038/nature06500;
RA   Kim J.-E., Chen J., Lou Z.;
RT   "DBC1 is a negative regulator of SIRT1.";
RL   Nature 451:583-586(2008).
RN   [42]
RP   INTERACTION WITH CCAR2, AND ACTIVITY REGULATION.
RX   PubMed=18235502; DOI=10.1038/nature06515;
RA   Zhao W., Kruse J.-P., Tang Y., Jung S.Y., Qin J., Gu W.;
RT   "Negative regulation of the deacetylase SIRT1 by DBC1.";
RL   Nature 451:587-590(2008).
RN   [43]
RP   PHOSPHORYLATION AT SER-14; SER-26; SER-27; SER-47; SER-159; SER-162;
RP   SER-172; SER-173; THR-530; THR-544; SER-545; THR-719 AND SER-747, AND
RP   MUTAGENESIS OF THR-530 AND SER-540.
RX   PubMed=19107194; DOI=10.1371/journal.pone.0004020;
RA   Sasaki T., Maier B., Koclega K.D., Chruszcz M., Gluba W., Stukenberg P.T.,
RA   Minor W., Scrable H.;
RT   "Phosphorylation regulates SIRT1 function.";
RL   PLoS ONE 3:E4020-E4020(2008).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-719, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [45]
RP   FUNCTION IN DEACETYLATION OF ATG5; ATG7 AND MAP1LC3B, AND FUNCTION IN
RP   AUTOPHAGY.
RX   PubMed=18296641; DOI=10.1073/pnas.0712145105;
RA   Lee I.H., Cao L., Mostoslavsky R., Lombard D.B., Liu J., Bruns N.E.,
RA   Tsokos M., Alt F.W., Finkel T.;
RT   "A role for the NAD-dependent deacetylase Sirt1 in the regulation of
RT   autophagy.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3374-3379(2008).
RN   [46]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [47]
RP   PHOSPHORYLATION AT SER-659 AND SER-661, AND MUTAGENESIS OF SER-659; SER-661
RP   AND SER-684.
RX   PubMed=19236849; DOI=10.1016/j.bbrc.2009.02.085;
RA   Zschoernig B., Mahlknecht U.;
RT   "Carboxy-terminal phosphorylation of SIRT1 by protein kinase CK2.";
RL   Biochem. Biophys. Res. Commun. 381:372-377(2009).
RN   [48]
RP   FUNCTION.
RX   PubMed=19220062; DOI=10.1021/bi802093g;
RA   Du J., Jiang H., Lin H.;
RT   "Investigating the ADP-ribosyltransferase activity of sirtuins with NAD
RT   analogues and 32P-NAD.";
RL   Biochemistry 48:2878-2890(2009).
RN   [49]
RP   INTERACTION WITH PPARA.
RX   PubMed=19356714; DOI=10.1016/j.cmet.2009.02.006;
RA   Purushotham A., Schug T.T., Xu Q., Surapureddi S., Guo X., Li X.;
RT   "Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and
RT   results in hepatic steatosis and inflammation.";
RL   Cell Metab. 9:327-338(2009).
RN   [50]
RP   FUNCTION, AND INTERACTION WITH CREBZF.
RX   PubMed=19690166; DOI=10.1074/jbc.m109.034165;
RA   Xie Y.B., Park J.H., Kim D.K., Hwang J.H., Oh S., Park S.B., Shong M.,
RA   Lee I.K., Choi H.S.;
RT   "Transcriptional corepressor SMILE recruits SIRT1 to inhibit nuclear
RT   receptor estrogen receptor-related receptor gamma transactivation.";
RL   J. Biol. Chem. 284:28762-28774(2009).
RN   [51]
RP   FUNCTION IN DEACETYLATION OF MYC, AND FUNCTION IN REGULATION OF MYC.
RX   PubMed=19364925; DOI=10.1083/jcb.200809167;
RA   Yuan J., Minter-Dykhouse K., Lou Z.;
RT   "A c-Myc-SIRT1 feedback loop regulates cell growth and transformation.";
RL   J. Cell Biol. 185:203-211(2009).
RN   [52]
RP   FUNCTION IN DEACETYLATION OF PCAF, AND FUNCTION IN DNA REPAIR.
RX   PubMed=19188449; DOI=10.1128/mcb.00552-08;
RA   Pediconi N., Guerrieri F., Vossio S., Bruno T., Belloni L., Schinzari V.,
RA   Scisciani C., Fanciulli M., Levrero M.;
RT   "hSirT1-dependent regulation of the PCAF-E2F1-p73 apoptotic pathway in
RT   response to DNA damage.";
RL   Mol. Cell. Biol. 29:1989-1998(2009).
RN   [53]
RP   PHOSPHORYLATION AT SER-27; SER-47 AND THR-530, MUTAGENESIS OF SER-27;
RP   SER-47 AND THR-530, AND SUBCELLULAR LOCATION.
RX   PubMed=20027304; DOI=10.1371/journal.pone.0008414;
RA   Nasrin N., Kaushik V.K., Fortier E., Wall D., Pearson K.J., de Cabo R.,
RA   Bordone L.;
RT   "JNK1 phosphorylates SIRT1 and promotes its enzymatic activity.";
RL   PLoS ONE 4:E8414-E8414(2009).
RN   [54]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-530; SER-535 AND THR-719, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [55]
RP   FUNCTION IN REGULATION OF STK11.
RX   PubMed=20203304; DOI=10.1161/circresaha.109.215483;
RA   Zu Y., Liu L., Lee M.Y., Xu C., Liang Y., Man R.Y., Vanhoutte P.M.,
RA   Wang Y.;
RT   "SIRT1 promotes proliferation and prevents senescence through targeting
RT   LKB1 in primary porcine aortic endothelial cells.";
RL   Circ. Res. 106:1384-1393(2010).
RN   [56]
RP   FUNCTION IN DNA REPAIR HOMOLOGOUS RECOMBINATION.
RX   PubMed=20097625; DOI=10.1016/j.dnarep.2009.12.020;
RA   Uhl M., Csernok A., Aydin S., Kreienberg R., Wiesmuller L., Gatz S.A.;
RT   "Role of SIRT1 in homologous recombination.";
RL   DNA Repair 9:383-393(2010).
RN   [57]
RP   INTERACTION WITH FOS AND JUN.
RX   PubMed=20042607; DOI=10.1074/jbc.m109.038604;
RA   Zhang R., Chen H.Z., Liu J.J., Jia Y.Y., Zhang Z.Q., Yang R.F., Zhang Y.,
RA   Xu J., Wei Y.S., Liu D.P., Liang C.C.;
RT   "SIRT1 suppresses activator protein-1 transcriptional activity and
RT   cyclooxygenase-2 expression in macrophages.";
RL   J. Biol. Chem. 285:7097-7110(2010).
RN   [58]
RP   FUNCTION IN DEACETYLATION OF KAT5.
RX   PubMed=20100829; DOI=10.1074/jbc.m109.087585;
RA   Wang J., Chen J.;
RT   "SIRT1 regulates autoacetylation and histone acetyltransferase activity of
RT   TIP60.";
RL   J. Biol. Chem. 285:11458-11464(2010).
RN   [59]
RP   SUBCELLULAR LOCATION.
RX   PubMed=20167603; DOI=10.1074/jbc.m110.102574;
RA   Guo X., Williams J.G., Schug T.T., Li X.;
RT   "DYRK1A and DYRK3 promote cell survival through phosphorylation and
RT   activation of SIRT1.";
RL   J. Biol. Chem. 285:13223-13232(2010).
RN   [60]
RP   FUNCTION IN DEACETYLATION OF SREBF1.
RX   PubMed=20817729; DOI=10.1074/jbc.m110.122978;
RA   Ponugoti B., Kim D.H., Xiao Z., Smith Z., Miao J., Zang M., Wu S.Y.,
RA   Chiang C.M., Veenstra T.D., Kemper J.K.;
RT   "SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic
RT   lipid metabolism.";
RL   J. Biol. Chem. 285:33959-33970(2010).
RN   [61]
RP   FUNCTION IN DEACETYLATION OF HIF1A, AND FUNCTION IN REGULATION OF HIF1A.
RX   PubMed=20620956; DOI=10.1016/j.molcel.2010.05.023;
RA   Lim J.H., Lee Y.M., Chun Y.S., Chen J., Kim J.E., Park J.W.;
RT   "Sirtuin 1 modulates cellular responses to hypoxia by deacetylating
RT   hypoxia-inducible factor 1alpha.";
RL   Mol. Cell 38:864-878(2010).
RN   [62]
RP   FUNCTION IN DEACETYLATION OF XPA.
RX   PubMed=20670893; DOI=10.1016/j.molcel.2010.07.006;
RA   Fan W., Luo J.;
RT   "SIRT1 regulates UV-induced DNA repair through deacetylating XPA.";
RL   Mol. Cell 39:247-258(2010).
RN   [63]
RP   FUNCTION IN DEACETYLATION OF APEX1, FUNCTION IN DNA REPAIR, MUTAGENESIS OF
RP   HIS-363, ACTIVE SITE, INDUCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19934257; DOI=10.1093/nar/gkp1039;
RA   Yamamori T., DeRicco J., Naqvi A., Hoffman T.A., Mattagajasingh I.,
RA   Kasuno K., Jung S.B., Kim C.S., Irani K.;
RT   "SIRT1 deacetylates APE1 and regulates cellular base excision repair.";
RL   Nucleic Acids Res. 38:832-845(2010).
RN   [64]
RP   FUNCTION, AND INTERACTION WITH NR0B2.
RX   PubMed=20375098; DOI=10.1093/nar/gkq227;
RA   Chanda D., Xie Y.B., Choi H.S.;
RT   "Transcriptional corepressor SHP recruits SIRT1 histone deacetylase to
RT   inhibit LRH-1 transactivation.";
RL   Nucleic Acids Res. 38:4607-4619(2010).
RN   [65]
RP   INTERACTION WITH TSC2.
RX   PubMed=20169165; DOI=10.1371/journal.pone.0009199;
RA   Ghosh H.S., McBurney M., Robbins P.D.;
RT   "SIRT1 negatively regulates the mammalian target of rapamycin.";
RL   PLoS ONE 5:E9199-E9199(2010).
RN   [66]
RP   ALTERNATIVE SPLICING (ISOFORM 2), FUNCTION (ISOFORM 2), INDUCTION (ISOFORM
RP   2), AND INTERACTION WITH TP53 AND RPS19BP1.
RX   PubMed=20975832; DOI=10.1371/journal.pone.0013502;
RA   Lynch C.J., Shah Z.H., Allison S.J., Ahmed S.U., Ford J., Warnock L.J.,
RA   Li H., Serrano M., Milner J.;
RT   "SIRT1 undergoes alternative splicing in a novel auto-regulatory loop with
RT   p53.";
RL   PLoS ONE 5:E13502-E13502(2010).
RN   [67]
RP   FUNCTION IN DNA REPAIR, AND SUPPRESSION OF XPC.
RX   PubMed=21149730; DOI=10.1073/pnas.1010377108;
RA   Ming M., Shea C.R., Guo X., Li X., Soltani K., Han W., He Y.Y.;
RT   "Regulation of global genome nucleotide excision repair by SIRT1 through
RT   xeroderma pigmentosum C.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:22623-22628(2010).
RN   [68]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-14 AND SER-47, CLEAVAGE OF INITIATOR METHIONINE [LARGE
RP   SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [69]
RP   FUNCTION IN DEACETYLATION OF HMGCS1.
RX   PubMed=21701047; DOI=10.18632/aging.100339;
RA   Hirschey M.D., Shimazu T., Capra J.A., Pollard K.S., Verdin E.;
RT   "SIRT1 and SIRT3 deacetylate homologous substrates: AceCS1,2 and
RT   HMGCS1,2.";
RL   Aging (Albany NY) 3:635-642(2011).
RN   [70]
RP   PROCESSING.
RX   PubMed=21305533; DOI=10.1002/art.30279;
RA   Dvir-Ginzberg M., Gagarina V., Lee E.J., Booth R., Gabay O., Hall D.J.;
RT   "Tumor necrosis factor alpha-mediated cleavage and inactivation of SirT1 in
RT   human osteoarthritic chondrocytes.";
RL   Arthritis Rheum. 63:2363-2373(2011).
RN   [71]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [72]
RP   FUNCTION IN DEACETYLATION OF XBP1, INTERACTION WITH XBP1, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=20955178; DOI=10.1042/bj20101293;
RA   Wang F.M., Chen Y.J., Ouyang H.J.;
RT   "Regulation of unfolded protein response modulator XBP1s by acetylation and
RT   deacetylation.";
RL   Biochem. J. 433:245-252(2011).
RN   [73]
RP   FUNCTION IN DEACETYLATION OF MECOM.
RX   PubMed=21555002; DOI=10.1016/j.bbagrm.2011.04.007;
RA   Pradhan A.K., Kuila N., Singh S., Chakraborty S.;
RT   "EVI1 up-regulates the stress responsive gene SIRT1 which triggers
RT   deacetylation and degradation of EVI1.";
RL   Biochim. Biophys. Acta 1809:269-275(2011).
RN   [74]
RP   INTERACTION WITH NR1I2.
RX   PubMed=21933665; DOI=10.1016/j.bcp.2011.09.006;
RA   Buler M., Aatsinki S.M., Skoumal R., Hakkola J.;
RT   "Energy sensing factors PGC-1alpha and SIRT1 modulate PXR expression and
RT   function.";
RL   Biochem. Pharmacol. 82:2008-2015(2011).
RN   [75]
RP   FUNCTION IN DEACETYLATION OF MYC, AND FUNCTION IN REGULATION OF MYC.
RX   PubMed=21807113; DOI=10.1016/j.biocel.2011.07.006;
RA   Mao B., Zhao G., Lv X., Chen H.Z., Xue Z., Yang B., Liu D.P., Liang C.C.;
RT   "Sirt1 deacetylates c-Myc and promotes c-Myc/Max association.";
RL   Int. J. Biochem. Cell Biol. 43:1573-1581(2011).
RN   [76]
RP   PHOSPHORYLATION BY STK4/MST1.
RX   PubMed=21212262; DOI=10.1074/jbc.m110.182543;
RA   Yuan F., Xie Q., Wu J., Bai Y., Mao B., Dong Y., Bi W., Ji G., Tao W.,
RA   Wang Y., Yuan Z.;
RT   "MST1 promotes apoptosis through regulating Sirt1-dependent p53
RT   deacetylation.";
RL   J. Biol. Chem. 286:6940-6945(2011).
RN   [77]
RP   FUNCTION IN APOPTOSIS, PHOSPHORYLATION AT SER-47, AND MUTAGENESIS OF SER-47
RP   AND PHE-474.
RX   PubMed=21471201; DOI=10.1074/jbc.m111.240598;
RA   Back J.H., Rezvani H.R., Zhu Y., Guyonnet-Duperat V., Athar M., Ratner D.,
RA   Kim A.L.;
RT   "Cancer cell survival following DNA damage-mediated premature senescence is
RT   regulated by mammalian target of rapamycin (mTOR)-dependent Inhibition of
RT   sirtuin 1.";
RL   J. Biol. Chem. 286:19100-19108(2011).
RN   [78]
RP   FUNCTION IN STABILIZATION OF SUV39H1.
RX   PubMed=21504832; DOI=10.1016/j.molcel.2011.02.034;
RA   Bosch-Presegue L., Raurell-Vila H., Marazuela-Duque A., Kane-Goldsmith N.,
RA   Valle A., Oliver J., Serrano L., Vaquero A.;
RT   "Stabilization of Suv39H1 by SirT1 is part of oxidative stress response and
RT   ensures genome protection.";
RL   Mol. Cell 42:210-223(2011).
RN   [79]
RP   FUNCTION IN DEACETYLATION OF DNMT1, AND FUNCTION IN REGULATION OF DNMT1.
RX   PubMed=21947282; DOI=10.1128/mcb.06147-11;
RA   Peng L., Yuan Z., Ling H., Fukasawa K., Robertson K., Olashaw N.,
RA   Koomen J., Chen J., Lane W.S., Seto E.;
RT   "SIRT1 deacetylates the DNA methyltransferase 1 (DNMT1) protein and alters
RT   its activities.";
RL   Mol. Cell. Biol. 31:4720-4734(2011).
RN   [80]
RP   FUNCTION IN REGULATION OF MYCN, AND INTERACTION WITH MYCN.
RX   PubMed=21698133; DOI=10.1371/journal.pgen.1002135;
RA   Marshall G.M., Liu P.Y., Gherardi S., Scarlett C.J., Bedalov A., Xu N.,
RA   Iraci N., Valli E., Ling D., Thomas W., van Bekkum M., Sekyere E.,
RA   Jankowski K., Trahair T., Mackenzie K.L., Haber M., Norris M.D.,
RA   Biankin A.V., Perini G., Liu T.;
RT   "SIRT1 promotes N-Myc oncogenesis through a positive feedback loop
RT   involving the effects of MKP3 and ERK on N-Myc protein stability.";
RL   PLoS Genet. 7:E1002135-E1002135(2011).
RN   [81]
RP   INTERACTION WITH HCFC1.
RX   PubMed=21909281; DOI=10.1371/journal.pgen.1002235;
RA   Rizki G., Iwata T.N., Li J., Riedel C.G., Picard C.L., Jan M., Murphy C.T.,
RA   Lee S.S.;
RT   "The evolutionarily conserved longevity determinants HCF-1 and
RT   SIR-2.1/SIRT1 collaborate to regulate DAF-16/FOXO.";
RL   PLoS Genet. 7:E1002235-E1002235(2011).
RN   [82]
RP   INTERACTION WITH SETD7, METHYLATION, AND MUTAGENESIS OF LYS-233; LYS-235;
RP   LYS-236 AND LYS-238.
RX   PubMed=21245319; DOI=10.1073/pnas.1019619108;
RA   Liu X., Wang D., Zhao Y., Tu B., Zheng Z., Wang L., Wang H., Gu W.,
RA   Roeder R.G., Zhu W.G.;
RT   "Methyltransferase Set7/9 regulates p53 activity by interacting with
RT   Sirtuin 1 (SIRT1).";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:1925-1930(2011).
RN   [83]
RP   FUNCTION IN DEACETYLATION OF AKT1, AND FUNCTION IN REGULATION OF AKT1.
RX   PubMed=21775285; DOI=10.1126/scisignal.2001465;
RA   Sundaresan N.R., Pillai V.B., Wolfgeher D., Samant S., Vasudevan P.,
RA   Parekh V., Raghuraman H., Cunningham J.M., Gupta M., Gupta M.P.;
RT   "The deacetylase SIRT1 promotes membrane localization and activation of Akt
RT   and PDK1 during tumorigenesis and cardiac hypertrophy.";
RL   Sci. Signal. 4:RA46-RA46(2011).
RN   [84]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-14; SER-47 AND THR-719, CLEAVAGE OF INITIATOR METHIONINE
RP   [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [85]
RP   FUNCTION (SIRTT1 75 KDA FRAGMENT), AND SUBCELLULAR LOCATION (75SIRT1).
RX   PubMed=21987377; DOI=10.1002/art.33407;
RA   Oppenheimer H., Gabay O., Meir H., Haze A., Kandel L., Liebergall M.,
RA   Gagarina V., Lee E.J., Dvir-Ginzberg M.;
RT   "75kDa SirT1 blocks TNFalpha-mediated apoptosis in human osteoarthritic
RT   chondrocytes.";
RL   Arthritis Rheum. 64:718-728(2012).
RN   [86]
RP   FUNCTION IN DEACETYLATION OF CIITA.
RX   PubMed=21890893; DOI=10.1093/nar/gkr651;
RA   Wu X., Kong X., Chen D., Li H., Zhao Y., Xia M., Fang M., Li P., Fang F.,
RA   Sun L., Tian W., Xu H., Yang Y., Qi X., Gao Y., Sha J., Chen Q., Xu Y.;
RT   "SIRT1 links CIITA deacetylation to MHC II activation.";
RL   Nucleic Acids Res. 39:9549-9558(2011).
RN   [87]
RP   FUNCTION, AND DEUBIQUITINATION BY USP22.
RX   PubMed=22542455; DOI=10.1016/j.molcel.2012.03.024;
RA   Lin Z., Yang H., Kong Q., Li J., Lee S.M., Gao B., Dong H., Wei J.,
RA   Song J., Zhang D.D., Fang D.;
RT   "USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1
RT   to suppress cell apoptosis and is required for mouse embryonic
RT   development.";
RL   Mol. Cell 46:484-494(2012).
RN   [88]
RP   FUNCTION IN DEACETYLATION OF PML.
RX   PubMed=22274616; DOI=10.1038/emboj.2012.1;
RA   Miki T., Xu Z., Chen-Goodspeed M., Liu M., Van Oort-Jansen A., Rea M.A.,
RA   Zhao Z., Lee C.C., Chang K.S.;
RT   "PML regulates PER2 nuclear localization and circadian function.";
RL   EMBO J. 31:1427-1439(2012).
RN   [89]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=22918831; DOI=10.1074/jbc.m112.359356;
RA   Yang C., Wu J., Sinha S.H., Neveu J.M., Zheng Y.G.;
RT   "Autoacetylation of the MYST lysine acetyltransferase MOF protein.";
RL   J. Biol. Chem. 287:34917-34926(2012).
RN   [90]
RP   FUNCTION IN DEACETYLATION OF PPARGC1A.
RX   PubMed=23142079; DOI=10.1016/j.molcel.2012.09.030;
RA   Dominy J.E. Jr., Lee Y., Jedrychowski M.P., Chim H., Jurczak M.J.,
RA   Camporez J.P., Ruan H.B., Feldman J., Pierce K., Mostoslavsky R.,
RA   Denu J.M., Clish C.B., Yang X., Shulman G.I., Gygi S.P., Puigserver P.;
RT   "The deacetylase Sirt6 activates the acetyltransferase GCN5 and suppresses
RT   hepatic gluconeogenesis.";
RL   Mol. Cell 48:900-913(2012).
RN   [91]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [92]
RP   FUNCTION IN DEACETYLATION OF FOXO3, AND FUNCTION IN REGULATION OF FOXO3.
RX   PubMed=21841822; DOI=10.1038/onc.2011.347;
RA   Wang F., Chan C.H., Chen K., Guan X., Lin H.K., Tong Q.;
RT   "Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3
RT   ubiquitination and degradation.";
RL   Oncogene 31:1546-1557(2012).
RN   [93]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [94]
RP   INTERACTION WITH CCAR2.
RX   PubMed=23352644; DOI=10.1016/j.canlet.2013.01.026;
RA   Kim W., Kim J.E.;
RT   "Deleted in breast cancer 1 (DBC1) deficiency results in apoptosis of
RT   breast cancer cells through impaired responses to UV-induced DNA damage.";
RL   Cancer Lett. 333:180-186(2013).
RN   [95]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14; SER-27; SER-47 AND
RP   THR-719, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [96]
RP   INTERACTION WITH PPARA.
RX   PubMed=24043310; DOI=10.1128/mcb.00087-13;
RA   Laurent G., de Boer V.C., Finley L.W., Sweeney M., Lu H., Schug T.T.,
RA   Cen Y., Jeong S.M., Li X., Sauve A.A., Haigis M.C.;
RT   "SIRT4 represses peroxisome proliferator-activated receptor alpha activity
RT   to suppress hepatic fat oxidation.";
RL   Mol. Cell. Biol. 33:4552-4561(2013).
RN   [97]
RP   FUNCTION.
RX   PubMed=24415752; DOI=10.1074/jbc.m113.512913;
RA   Nin V., Chini C.C., Escande C., Capellini V., Chini E.N.;
RT   "Deleted in breast cancer 1 (DBC1) protein regulates hepatic
RT   gluconeogenesis.";
RL   J. Biol. Chem. 289:5518-5527(2014).
RN   [98]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14 AND SER-27, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [99]
RP   INTERACTION WITH CCAR2 AND TP53, MUTAGENESIS OF 256-ILE-ILE-257 AND
RP   HIS-363, AND ACTIVE SITE.
RX   PubMed=25406032; DOI=10.1038/ncomms6483;
RA   Park J.H., Lee S.W., Yang S.W., Yoo H.M., Park J.M., Seong M.W., Ka S.H.,
RA   Oh K.H., Jeon Y.J., Chung C.H.;
RT   "Modification of DBC1 by SUMO2/3 is crucial for p53-mediated apoptosis in
RT   response to DNA damage.";
RL   Nat. Commun. 5:5483-5483(2014).
RN   [100]
RP   INTERACTION WITH CHEK2.
RX   PubMed=25361978; DOI=10.1093/nar/gku1065;
RA   Magni M., Ruscica V., Buscemi G., Kim J.E., Nachimuthu B.T., Fontanella E.,
RA   Delia D., Zannini L.;
RT   "Chk2 and REGgamma-dependent DBC1 regulation in DNA damage induced
RT   apoptosis.";
RL   Nucleic Acids Res. 42:13150-13160(2014).
RN   [101]
RP   FUNCTION IN DEACETYLATION OF CTNB1.
RX   PubMed=24824780; DOI=10.1002/ijc.28967;
RA   Pangon L., Mladenova D., Watkins L., Van Kralingen C., Currey N.,
RA   Al-Sohaily S., Lecine P., Borg J.P., Kohonen-Corish M.R.;
RT   "MCC inhibits beta-catenin transcriptional activity by sequestering DBC1 in
RT   the cytoplasm.";
RL   Int. J. Cancer 136:55-64(2015).
RN   [102]
RP   INTERACTION WITH NR1H3.
RX   PubMed=25661920; DOI=10.1016/j.jsbmb.2015.02.001;
RA   Sakurabashi A., Wada-Hiraike O., Hirano M., Fu H., Isono W., Fukuda T.,
RA   Morita Y., Tanikawa M., Miyamoto Y., Oda K., Kawana K., Osuga Y., Fujii T.;
RT   "CCAR2 negatively regulates nuclear receptor LXRalpha by competing with
RT   SIRT1 deacetylase.";
RL   J. Steroid Biochem. Mol. Biol. 149:80-88(2015).
RN   [103]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVE SITE, AND MUTAGENESIS OF HIS-363.
RX   PubMed=28497810; DOI=10.1038/cr.2017.68;
RA   Wei W., Liu X., Chen J., Gao S., Lu L., Zhang H., Ding G., Wang Z.,
RA   Chen Z., Shi T., Li J., Yu J., Wong J.;
RT   "Class I histone deacetylases are major histone decrotonylases: evidence
RT   for critical and broad function of histone crotonylation in
RT   transcription.";
RL   Cell Res. 27:898-915(2017).
RN   [104]
RP   INTERACTION WITH PACS2.
RX   PubMed=29656858; DOI=10.1016/j.ajhg.2018.03.005;
RG   DDD Study;
RG   C4RCD Research Group;
RA   Olson H.E., Jean-Marcais N., Yang E., Heron D., Tatton-Brown K.,
RA   van der Zwaag P.A., Bijlsma E.K., Krock B.L., Backer E., Kamsteeg E.J.,
RA   Sinnema M., Reijnders M.R.F., Bearden D., Begtrup A., Telegrafi A.,
RA   Lunsing R.J., Burglen L., Lesca G., Cho M.T., Smith L.A., Sheidley B.R.,
RA   Moufawad El Achkar C., Pearl P.L., Poduri A., Skraban C.M., Tarpinian J.,
RA   Nesbitt A.I., Fransen van de Putte D.E., Ruivenkamp C.A.L., Rump P.,
RA   Chatron N., Sabatier I., De Bellescize J., Guibaud L., Sweetser D.A.,
RA   Waxler J.L., Wierenga K.J., Donadieu J., Narayanan V., Ramsey K.M.,
RA   Nava C., Riviere J.B., Vitobello A., Tran Mau-Them F., Philippe C.,
RA   Bruel A.L., Duffourd Y., Thomas L., Lelieveld S.H., Schuurs-Hoeijmakers J.,
RA   Brunner H.G., Keren B., Thevenon J., Faivre L., Thomas G.,
RA   Thauvin-Robinet C.;
RT   "A recurrent de novo PACS2 heterozygous missense variant causes neonatal-
RT   onset developmental epileptic encephalopathy, facial dysmorphism, and
RT   cerebellar dysgenesis.";
RL   Am. J. Hum. Genet. 102:995-1007(2018).
RN   [105]
RP   FUNCTION, AND INTERACTION WITH MORN3.
RX   PubMed=29681526; DOI=10.1016/j.chembiol.2018.03.010;
RA   Liang L., Wang H., Shi H., Li Z., Yao H., Bu Z., Song N., Li C., Xiang D.,
RA   Zhang Y., Wang J., Hu Y., Xu Q., Ma Y., Cheng Z., Wang Y., Zhao S.,
RA   Qian J., Chen Y., Fang J.Y., Xu J.;
RT   "A Designed Peptide Targets Two Types of Modifications of p53 with Anti-
RT   cancer Activity.";
RL   Cell Chem. Biol. 25:761-774.e5(2018).
RN   [106]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=29765047; DOI=10.1038/s41467-018-04363-w;
RA   Li T.Y., Song L., Sun Y., Li J., Yi C., Lam S.M., Xu D., Zhou L., Li X.,
RA   Yang Y., Zhang C.S., Xie C., Huang X., Shui G., Lin S.Y., Reue K.,
RA   Lin S.C.;
RT   "Tip60-mediated lipin 1 acetylation and ER translocation determine
RT   triacylglycerol synthesis rate.";
RL   Nat. Commun. 9:1916-1916(2018).
RN   [107]
RP   FUNCTION IN DEACETYLATION OF PCK1.
RX   PubMed=30193097; DOI=10.1016/j.molcel.2018.07.031;
RA   Latorre-Muro P., Baeza J., Armstrong E.A., Hurtado-Guerrero R., Corzana F.,
RA   Wu L.E., Sinclair D.A., Lopez-Buesa P., Carrodeguas J.A., Denu J.M.;
RT   "Dynamic acetylation of phosphoenolpyruvate carboxykinase toggles enzyme
RT   activity between gluconeogenic and anaplerotic reactions.";
RL   Mol. Cell 71:718-732(2018).
RN   [108]
RP   INTERACTION WITH PUS7.
RX   PubMed=31451225; DOI=10.1016/j.bbrc.2019.08.097;
RA   Dalal S., Deshmukh P., Unni S., Padavattan S., Padmanabhan B.;
RT   "Biochemical insight into pseudouridine synthase 7 (PUS7) as a novel
RT   interactor of sirtuin, SIRT1.";
RL   Biochem. Biophys. Res. Commun. 518:598-604(2019).
RN   [109]
RP   FUNCTION.
RX   PubMed=31722219; DOI=10.1016/j.celrep.2019.10.028;
RA   Wang T., Zou Y., Huang N., Teng J., Chen J.;
RT   "CCDC84 Acetylation Oscillation Regulates Centrosome Duplication by
RT   Modulating HsSAS-6 Degradation.";
RL   Cell Rep. 29:2078-2091.e5(2019).
RN   [110]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=30409912; DOI=10.1074/jbc.ra118.003844;
RA   Zhao G., Cheng Y., Gui P., Cui M., Liu W., Wang W., Wang X., Ali M.,
RA   Dou Z., Niu L., Liu H., Anderson L., Ruan K., Hong J., Yao X.;
RT   "Dynamic acetylation of the kinetochore-associated protein HEC1 ensures
RT   accurate microtubule-kinetochore attachment.";
RL   J. Biol. Chem. 294:576-592(2019).
RN   [111]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-363.
RX   PubMed=32538779; DOI=10.7554/elife.55828;
RA   Meng F., Qian M., Peng B., Peng L., Wang X., Zheng K., Liu Z., Tang X.,
RA   Zhang S., Sun S., Cao X., Pang Q., Zhao B., Ma W., Songyang Z., Xu B.,
RA   Zhu W.G., Xu X., Liu B.;
RT   "Synergy between SIRT1 and SIRT6 helps recognize DNA breaks and potentiates
RT   the DNA damage response and repair in humans and mice.";
RL   Elife 9:0-0(2020).
RN   [112]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-363.
RX   PubMed=32034146; DOI=10.1038/s41467-020-14564-x;
RA   Wang J., He H., Chen B., Jiang G., Cao L., Jiang H., Zhang G., Chen J.,
RA   Huang J., Yang B., Zhou C., Liu T.;
RT   "Acetylation of XPF by TIP60 facilitates XPF-ERCC1 complex assembly and
RT   activation.";
RL   Nat. Commun. 11:786-786(2020).
RN   [113]
RP   INTERACTION WITH TULP3.
RX   PubMed=35397207; DOI=10.1016/j.ajhg.2022.03.015;
RA   Devane J., Ott E., Olinger E.G., Epting D., Decker E., Friedrich A.,
RA   Bachmann N., Renschler G., Eisenberger T., Briem-Richter A., Grabhorn E.F.,
RA   Powell L., Wilson I.J., Rice S.J., Miles C.G., Wood K., Trivedi P.,
RA   Hirschfield G., Pietrobattista A., Wohler E., Mezina A., Sobreira N.,
RA   Agolini E., Maggiore G., Dahmer-Heath M., Yilmaz A., Boerries M.,
RA   Metzger P., Schell C., Gruenewald I., Konrad M., Koenig J., Schlevogt B.,
RA   Sayer J.A., Bergmann C.;
RT   "Progressive liver, kidney, and heart degeneration in children and adults
RT   affected by TULP3 mutations.";
RL   Am. J. Hum. Genet. 109:928-943(2022).
RN   [114]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVE SITE, AND MUTAGENESIS OF HIS-363.
RX   PubMed=38512451; DOI=10.1172/jci174587;
RA   Ju J., Zhang H., Lin M., Yan Z., An L., Cao Z., Geng D., Yue J., Tang Y.,
RA   Tian L., Chen F., Han Y., Wang W., Zhao S., Jiao S., Zhou Z.;
RT   "The alanyl-tRNA synthetase AARS1 moonlights as a lactyltransferase to
RT   promote YAP signaling in gastric cancer.";
RL   J. Clin. Invest. 134:0-0(2024).
CC   -!- FUNCTION: NAD-dependent protein deacetylase that links transcriptional
CC       regulation directly to intracellular energetics and participates in the
CC       coordination of several separated cellular functions such as cell
CC       cycle, response to DNA damage, metabolism, apoptosis and autophagy
CC       (PubMed:11672523, PubMed:12006491, PubMed:14976264, PubMed:14980222,
CC       PubMed:15126506, PubMed:15152190, PubMed:15205477, PubMed:15469825,
CC       PubMed:15692560, PubMed:16079181, PubMed:16166628, PubMed:16892051,
CC       PubMed:16998810, PubMed:17283066, PubMed:17290224, PubMed:17334224,
CC       PubMed:17505061, PubMed:17612497, PubMed:17620057, PubMed:17936707,
CC       PubMed:18203716, PubMed:18296641, PubMed:18662546, PubMed:18687677,
CC       PubMed:19188449, PubMed:19220062, PubMed:19364925, PubMed:19690166,
CC       PubMed:19934257, PubMed:20097625, PubMed:20100829, PubMed:20203304,
CC       PubMed:20375098, PubMed:20620956, PubMed:20670893, PubMed:20817729,
CC       PubMed:20955178, PubMed:21149730, PubMed:21245319, PubMed:21471201,
CC       PubMed:21504832, PubMed:21555002, PubMed:21698133, PubMed:21701047,
CC       PubMed:21775285, PubMed:21807113, PubMed:21841822, PubMed:21890893,
CC       PubMed:21947282, PubMed:22274616, PubMed:22918831, PubMed:24415752,
CC       PubMed:24824780, PubMed:29681526, PubMed:29765047, PubMed:30409912).
CC       Can modulate chromatin function through deacetylation of histones and
CC       can promote alterations in the methylation of histones and DNA, leading
CC       to transcriptional repression (PubMed:15469825). Deacetylates a broad
CC       range of transcription factors and coregulators, thereby regulating
CC       target gene expression positively and negatively (PubMed:14976264,
CC       PubMed:14980222, PubMed:15152190). Serves as a sensor of the cytosolic
CC       ratio of NAD(+)/NADH which is altered by glucose deprivation and
CC       metabolic changes associated with caloric restriction
CC       (PubMed:15205477). Is essential in skeletal muscle cell differentiation
CC       and in response to low nutrients mediates the inhibitory effect on
CC       skeletal myoblast differentiation which also involves 5'-AMP-activated
CC       protein kinase (AMPK) and nicotinamide phosphoribosyltransferase
CC       (NAMPT) (By similarity). Component of the eNoSC (energy-dependent
CC       nucleolar silencing) complex, a complex that mediates silencing of rDNA
CC       in response to intracellular energy status and acts by recruiting
CC       histone-modifying enzymes (PubMed:18485871). The eNoSC complex is able
CC       to sense the energy status of cell: upon glucose starvation, elevation
CC       of NAD(+)/NADP(+) ratio activates SIRT1, leading to histone H3
CC       deacetylation followed by dimethylation of H3 at 'Lys-9' (H3K9me2) by
CC       SUV39H1 and the formation of silent chromatin in the rDNA locus
CC       (PubMed:18485871, PubMed:21504832). Deacetylates 'Lys-266' of SUV39H1,
CC       leading to its activation (PubMed:21504832). Inhibits skeletal muscle
CC       differentiation by deacetylating PCAF and MYOD1 (PubMed:19188449).
CC       Deacetylates H2A and 'Lys-26' of H1-4 (PubMed:15469825). Deacetylates
CC       'Lys-16' of histone H4 (in vitro). Involved in NR0B2/SHP corepression
CC       function through chromatin remodeling: Recruited to LRH1 target gene
CC       promoters by NR0B2/SHP thereby stimulating histone H3 and H4
CC       deacetylation leading to transcriptional repression (PubMed:20375098).
CC       Proposed to contribute to genomic integrity via positive regulation of
CC       telomere length; however, reports on localization to pericentromeric
CC       heterochromatin are conflicting (By similarity). Proposed to play a
CC       role in constitutive heterochromatin (CH) formation and/or maintenance
CC       through regulation of the available pool of nuclear SUV39H1
CC       (PubMed:15469825, PubMed:18004385). Upon oxidative/metabolic stress
CC       decreases SUV39H1 degradation by inhibiting SUV39H1 polyubiquitination
CC       by MDM2 (PubMed:18004385, PubMed:21504832). This increase in SUV39H1
CC       levels enhances SUV39H1 turnover in CH, which in turn seems to
CC       accelerate renewal of the heterochromatin which correlates with greater
CC       genomic integrity during stress response (PubMed:18004385,
CC       PubMed:21504832). Deacetylates 'Lys-382' of p53/TP53 and impairs its
CC       ability to induce transcription-dependent proapoptotic program and
CC       modulate cell senescence (PubMed:11672523, PubMed:12006491,
CC       PubMed:22542455). Deacetylates TAF1B and thereby represses rDNA
CC       transcription by the RNA polymerase I (By similarity). Deacetylates
CC       MYC, promotes the association of MYC with MAX and decreases MYC
CC       stability leading to compromised transformational capability
CC       (PubMed:19364925, PubMed:21807113). Deacetylates FOXO3 in response to
CC       oxidative stress thereby increasing its ability to induce cell cycle
CC       arrest and resistance to oxidative stress but inhibiting FOXO3-mediated
CC       induction of apoptosis transcriptional activity; also leading to FOXO3
CC       ubiquitination and protesomal degradation (PubMed:14976264,
CC       PubMed:14980222, PubMed:21841822). Appears to have a similar effect on
CC       MLLT7/FOXO4 in regulation of transcriptional activity and apoptosis
CC       (PubMed:15126506). Deacetylates DNMT1; thereby impairs DNMT1
CC       methyltransferase-independent transcription repressor activity,
CC       modulates DNMT1 cell cycle regulatory function and DNMT1-mediated gene
CC       silencing (PubMed:21947282). Deacetylates RELA/NF-kappa-B p65 thereby
CC       inhibiting its transactivating potential and augments apoptosis in
CC       response to TNF-alpha (PubMed:15152190). Deacetylates HIF1A,
CC       KAT5/TIP60, RB1 and HIC1 (PubMed:17283066, PubMed:17620057,
CC       PubMed:20100829, PubMed:20620956). Deacetylates FOXO1 resulting in its
CC       nuclear retention and enhancement of its transcriptional activity
CC       leading to increased gluconeogenesis in liver (PubMed:15692560).
CC       Inhibits E2F1 transcriptional activity and apoptotic function, possibly
CC       by deacetylation (PubMed:16892051). Involved in HES1- and HEY2-mediated
CC       transcriptional repression (PubMed:12535671). In cooperation with MYCN
CC       seems to be involved in transcriptional repression of DUSP6/MAPK3
CC       leading to MYCN stabilization by phosphorylation at 'Ser-62'
CC       (PubMed:21698133). Deacetylates MEF2D (PubMed:16166628). Required for
CC       antagonist-mediated transcription suppression of AR-dependent genes
CC       which may be linked to local deacetylation of histone H3
CC       (PubMed:17505061). Represses HNF1A-mediated transcription (By
CC       similarity). Required for the repression of ESRRG by CREBZF
CC       (PubMed:19690166). Deacetylates NR1H3 and NR1H2 and deacetylation of
CC       NR1H3 at 'Lys-434' positively regulates transcription of NR1H3:RXR
CC       target genes, promotes NR1H3 proteasomal degradation and results in
CC       cholesterol efflux; a promoter clearing mechanism after reach round of
CC       transcription is proposed (PubMed:17936707). Involved in lipid
CC       metabolism: deacetylates LPIN1, thereby inhibiting diacylglycerol
CC       synthesis (PubMed:20817729, PubMed:29765047). Implicated in regulation
CC       of adipogenesis and fat mobilization in white adipocytes by repression
CC       of PPARG which probably involves association with NCOR1 and SMRT/NCOR2
CC       (By similarity). Deacetylates p300/EP300 and PRMT1 (By similarity).
CC       Deacetylates ACSS2 leading to its activation, and HMGCS1 deacetylation
CC       (PubMed:21701047). Involved in liver and muscle metabolism. Through
CC       deacetylation and activation of PPARGC1A is required to activate fatty
CC       acid oxidation in skeletal muscle under low-glucose conditions and is
CC       involved in glucose homeostasis (PubMed:23142079). Involved in
CC       regulation of PPARA and fatty acid beta-oxidation in liver. Involved in
CC       positive regulation of insulin secretion in pancreatic beta cells in
CC       response to glucose; the function seems to imply transcriptional
CC       repression of UCP2. Proposed to deacetylate IRS2 thereby facilitating
CC       its insulin-induced tyrosine phosphorylation. Deacetylates SREBF1
CC       isoform SREBP-1C thereby decreasing its stability and transactivation
CC       in lipogenic gene expression (PubMed:17290224, PubMed:20817729).
CC       Involved in DNA damage response by repressing genes which are involved
CC       in DNA repair, such as XPC and TP73, deacetylating XRCC6/Ku70, and
CC       facilitating recruitment of additional factors to sites of damaged DNA,
CC       such as SIRT1-deacetylated NBN can recruit ATM to initiate DNA repair
CC       and SIRT1-deacetylated XPA interacts with RPA2 (PubMed:15205477,
CC       PubMed:16998810, PubMed:17334224, PubMed:17612497, PubMed:20670893,
CC       PubMed:21149730). Also involved in DNA repair of DNA double-strand
CC       breaks by homologous recombination and specifically single-strand
CC       annealing independently of XRCC6/Ku70 and NBN (PubMed:15205477,
CC       PubMed:17334224, PubMed:20097625). Promotes DNA double-strand breaks by
CC       mediating deacetylation of SIRT6 (PubMed:32538779). Transcriptional
CC       suppression of XPC probably involves an E2F4:RBL2 suppressor complex
CC       and protein kinase B (AKT) signaling. Transcriptional suppression of
CC       TP73 probably involves E2F4 and PCAF. Deacetylates WRN thereby
CC       regulating its helicase and exonuclease activities and regulates WRN
CC       nuclear translocation in response to DNA damage (PubMed:18203716).
CC       Deacetylates APEX1 at 'Lys-6' and 'Lys-7' and stimulates cellular AP
CC       endonuclease activity by promoting the association of APEX1 to XRCC1
CC       (PubMed:19934257). Catalyzes deacetylation of ERCC4/XPF, thereby
CC       impairing interaction with ERCC1 and nucleotide excision repair (NER)
CC       (PubMed:32034146). Increases p53/TP53-mediated transcription-
CC       independent apoptosis by blocking nuclear translocation of cytoplasmic
CC       p53/TP53 and probably redirecting it to mitochondria. Deacetylates
CC       XRCC6/Ku70 at 'Lys-539' and 'Lys-542' causing it to sequester BAX away
CC       from mitochondria thereby inhibiting stress-induced apoptosis. Is
CC       involved in autophagy, presumably by deacetylating ATG5, ATG7 and
CC       MAP1LC3B/ATG8 (PubMed:18296641). Deacetylates AKT1 which leads to
CC       enhanced binding of AKT1 and PDK1 to PIP3 and promotes their activation
CC       (PubMed:21775285). Proposed to play role in regulation of STK11/LBK1-
CC       dependent AMPK signaling pathways implicated in cellular senescence
CC       which seems to involve the regulation of the acetylation status of
CC       STK11/LBK1. Can deacetylate STK11/LBK1 and thereby increase its
CC       activity, cytoplasmic localization and association with STRAD; however,
CC       the relevance of such activity in normal cells is unclear
CC       (PubMed:18687677, PubMed:20203304). In endothelial cells is shown to
CC       inhibit STK11/LBK1 activity and to promote its degradation.
CC       Deacetylates SMAD7 at 'Lys-64' and 'Lys-70' thereby promoting its
CC       degradation. Deacetylates CIITA and augments its MHC class II
CC       transactivation and contributes to its stability (PubMed:21890893).
CC       Deacetylates MECOM/EVI1 (PubMed:21555002). Deacetylates PML at 'Lys-
CC       487' and this deacetylation promotes PML control of PER2 nuclear
CC       localization (PubMed:22274616). During the neurogenic transition,
CC       represses selective NOTCH1-target genes through histone deacetylation
CC       in a BCL6-dependent manner and leading to neuronal differentiation.
CC       Regulates the circadian expression of several core clock genes,
CC       including BMAL1, RORC, PER2 and CRY1 and plays a critical role in
CC       maintaining a controlled rhythmicity in histone acetylation, thereby
CC       contributing to circadian chromatin remodeling (PubMed:18662546).
CC       Deacetylates BMAL1 and histones at the circadian gene promoters in
CC       order to facilitate repression by inhibitory components of the
CC       circadian oscillator (By similarity). Deacetylates PER2, facilitating
CC       its ubiquitination and degradation by the proteasome (By similarity).
CC       Protects cardiomyocytes against palmitate-induced apoptosis (By
CC       similarity). Deacetylates XBP1 isoform 2; deacetylation decreases
CC       protein stability of XBP1 isoform 2 and inhibits its transcriptional
CC       activity (PubMed:20955178). Deacetylates PCK1 and directs its activity
CC       toward phosphoenolpyruvate production promoting gluconeogenesis
CC       (PubMed:30193097). Involved in the CCAR2-mediated regulation of PCK1
CC       and NR1D1 (PubMed:24415752). Deacetylates CTNB1 at 'Lys-49'
CC       (PubMed:24824780). In POMC (pro-opiomelanocortin) neurons, required for
CC       leptin-induced activation of PI3K signaling (By similarity).
CC       Deacetylates SOX9; promoting SOX9 nuclear localization and
CC       transactivation activity (By similarity). Involved in the regulation of
CC       centrosome duplication: deacetylates CENATAC in G1 phase, allowing for
CC       SASS6 accumulation on the centrosome and subsequent procentriole
CC       assembly (PubMed:31722219). Deacetylates NDC80/HEC1 (PubMed:30409912).
CC       In addition to protein deacetylase activity, also acts as a protein-
CC       lysine deacylase by mediating protein delactylation, depropionylation
CC       and decrotonylation (PubMed:28497810, PubMed:38512451). Mediates
CC       depropionylation of Osterix (SP7) (By similarity). Catalyzes
CC       decrotonylation of histones; it however does not represent a major
CC       histone decrotonylase (PubMed:28497810). Mediates protein delactylation
CC       of TEAD1 and YAP1 (PubMed:38512451). {ECO:0000250|UniProtKB:Q923E4,
CC       ECO:0000269|PubMed:11672523, ECO:0000269|PubMed:12006491,
CC       ECO:0000269|PubMed:12535671, ECO:0000269|PubMed:14976264,
CC       ECO:0000269|PubMed:14980222, ECO:0000269|PubMed:15126506,
CC       ECO:0000269|PubMed:15152190, ECO:0000269|PubMed:15205477,
CC       ECO:0000269|PubMed:15469825, ECO:0000269|PubMed:15692560,
CC       ECO:0000269|PubMed:16079181, ECO:0000269|PubMed:16166628,
CC       ECO:0000269|PubMed:16892051, ECO:0000269|PubMed:16998810,
CC       ECO:0000269|PubMed:17283066, ECO:0000269|PubMed:17290224,
CC       ECO:0000269|PubMed:17334224, ECO:0000269|PubMed:17505061,
CC       ECO:0000269|PubMed:17612497, ECO:0000269|PubMed:17620057,
CC       ECO:0000269|PubMed:17936707, ECO:0000269|PubMed:18203716,
CC       ECO:0000269|PubMed:18296641, ECO:0000269|PubMed:18485871,
CC       ECO:0000269|PubMed:18662546, ECO:0000269|PubMed:18687677,
CC       ECO:0000269|PubMed:19188449, ECO:0000269|PubMed:19220062,
CC       ECO:0000269|PubMed:19364925, ECO:0000269|PubMed:19690166,
CC       ECO:0000269|PubMed:19934257, ECO:0000269|PubMed:20097625,
CC       ECO:0000269|PubMed:20100829, ECO:0000269|PubMed:20203304,
CC       ECO:0000269|PubMed:20375098, ECO:0000269|PubMed:20620956,
CC       ECO:0000269|PubMed:20670893, ECO:0000269|PubMed:20817729,
CC       ECO:0000269|PubMed:20955178, ECO:0000269|PubMed:21149730,
CC       ECO:0000269|PubMed:21245319, ECO:0000269|PubMed:21471201,
CC       ECO:0000269|PubMed:21504832, ECO:0000269|PubMed:21555002,
CC       ECO:0000269|PubMed:21698133, ECO:0000269|PubMed:21701047,
CC       ECO:0000269|PubMed:21775285, ECO:0000269|PubMed:21807113,
CC       ECO:0000269|PubMed:21841822, ECO:0000269|PubMed:21890893,
CC       ECO:0000269|PubMed:21947282, ECO:0000269|PubMed:22274616,
CC       ECO:0000269|PubMed:22542455, ECO:0000269|PubMed:22918831,
CC       ECO:0000269|PubMed:23142079, ECO:0000269|PubMed:24415752,
CC       ECO:0000269|PubMed:24824780, ECO:0000269|PubMed:28497810,
CC       ECO:0000269|PubMed:29681526, ECO:0000269|PubMed:29765047,
CC       ECO:0000269|PubMed:30193097, ECO:0000269|PubMed:30409912,
CC       ECO:0000269|PubMed:31722219, ECO:0000269|PubMed:32034146,
CC       ECO:0000269|PubMed:32538779, ECO:0000269|PubMed:38512451}.
CC   -!- FUNCTION: [Isoform 2]: Deacetylates 'Lys-382' of p53/TP53, however with
CC       lower activity than isoform 1. In combination, the two isoforms exert
CC       an additive effect. Isoform 2 regulates p53/TP53 expression and
CC       cellular stress response and is in turn repressed by p53/TP53
CC       presenting a SIRT1 isoform-dependent auto-regulatory loop.
CC       {ECO:0000269|PubMed:20975832}.
CC   -!- FUNCTION: [SirtT1 75 kDa fragment]: Catalytically inactive 75SirT1 may
CC       be involved in regulation of apoptosis. May be involved in protecting
CC       chondrocytes from apoptotic death by associating with cytochrome C and
CC       interfering with apoptosome assembly. {ECO:0000269|PubMed:21987377}.
CC   -!- FUNCTION: (Microbial infection) In case of HIV-1 infection, interacts
CC       with and deacetylates the viral Tat protein. The viral Tat protein
CC       inhibits SIRT1 deacetylation activity toward RELA/NF-kappa-B p65,
CC       thereby potentiates its transcriptional activity and SIRT1 is proposed
CC       to contribute to T-cell hyperactivation during infection.
CC       {ECO:0000269|PubMed:18329615}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=N(6)-acetyl-L-lysyl-[protein] + NAD(+) + H2O = 2''-O-acetyl-
CC         ADP-D-ribose + nicotinamide + L-lysyl-[protein];
CC         Xref=Rhea:RHEA:43636, Rhea:RHEA-COMP:9752, Rhea:RHEA-COMP:10731,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:17154, ChEBI:CHEBI:29969,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:61930, ChEBI:CHEBI:83767;
CC         EC=2.3.1.286; Evidence={ECO:0000255|PROSITE-ProRule:PRU00236,
CC         ECO:0000269|PubMed:12006491, ECO:0000269|PubMed:22918831,
CC         ECO:0000269|PubMed:29765047, ECO:0000269|PubMed:30409912,
CC         ECO:0000269|PubMed:32034146, ECO:0000269|PubMed:32538779};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=N(6)-propanoyl-L-lysyl-[protein] + NAD(+) + H2O = 3''-O-
CC         propanoyl-ADP-D-ribose + nicotinamide + L-lysyl-[protein];
CC         Xref=Rhea:RHEA:23500, Rhea:RHEA-COMP:9752, Rhea:RHEA-COMP:13758,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:17154, ChEBI:CHEBI:29969,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:138019, ChEBI:CHEBI:145015;
CC         Evidence={ECO:0000250|UniProtKB:Q923E4};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:23501;
CC         Evidence={ECO:0000250|UniProtKB:Q923E4};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=N(6)-(2E)-butenoyl-L-lysyl-[protein] + NAD(+) + H2O = 2''-O-
CC         (2E)-but-2-enoyl-ADP-D-ribose + nicotinamide + L-lysyl-[protein];
CC         Xref=Rhea:RHEA:69332, Rhea:RHEA-COMP:9752, Rhea:RHEA-COMP:13707,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:17154, ChEBI:CHEBI:29969,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:137954, ChEBI:CHEBI:183235;
CC         Evidence={ECO:0000269|PubMed:28497810};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:69333;
CC         Evidence={ECO:0000269|PubMed:28497810};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=N(6)-[(S)-lactoyl]-L-lysyl-[protein] + NAD(+) + H2O = 2''-O-
CC         (S)-lactoyl-ADP-D-ribose + nicotinamide + L-lysyl-[protein];
CC         Xref=Rhea:RHEA:80287, Rhea:RHEA-COMP:9752, Rhea:RHEA-COMP:19466,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:17154, ChEBI:CHEBI:29969,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:231484, ChEBI:CHEBI:231527;
CC         Evidence={ECO:0000269|PubMed:38512451};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:80288;
CC         Evidence={ECO:0000269|PubMed:38512451};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000250|UniProtKB:Q8IXJ6};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250|UniProtKB:Q8IXJ6};
CC   -!- ACTIVITY REGULATION: Inhibited by nicotinamide. Activated by
CC       resveratrol (3,5,4'-trihydroxy-trans-stilbene), butein (3,4,2',4'-
CC       tetrahydroxychalcone), piceatannol (3,5,3',4'-tetrahydroxy-trans-
CC       stilbene), Isoliquiritigenin (4,2',4'-trihydroxychalcone), fisetin
CC       (3,7,3',4'-tetrahydroxyflavone) and quercetin (3,5,7,3',4'-
CC       pentahydroxyflavone). MAPK8/JNK1 and RPS19BP1/AROS act as positive
CC       regulators of deacetylation activity. Negatively regulated by CCAR2.
CC       {ECO:0000269|PubMed:12297502, ECO:0000269|PubMed:12939617,
CC       ECO:0000269|PubMed:18235501, ECO:0000269|PubMed:18235502}.
CC   -!- SUBUNIT: Interacts with XBP1 isoform 2 (PubMed:20955178). Found in a
CC       complex with PCAF and MYOD1. Interacts with FOXO1; the interaction
CC       deacetylates FOXO1, resulting in its nuclear retention and promotion of
CC       its transcriptional activity Component of the eNoSC complex, composed
CC       of SIRT1, SUV39H1 and RRP8. Interacts with HES1, HEY2 and PML.
CC       Interacts with RPS19BP1/AROS. Interacts with CCAR2 (via N-terminus);
CC       the interaction disrupts the interaction between SIRT1 and p53/TP53.
CC       Interacts with SETD7; the interaction induces the dissociation of SIRT1
CC       from p53/TP53 and increases p53/TP53 activity. Interacts with MYCN,
CC       NR1I2, CREBZF, TSC2, TLE1, FOS, JUN, NR0B2, PPARG, NCOR, IRS1, IRS2 and
CC       NMNAT1. Interacts with HNF1A; the interaction occurs under nutrient
CC       restriction. Interacts with SUZ12; the interaction mediates the
CC       association with the PRC4 histone methylation complex which is specific
CC       as an association with PCR2 and PCR3 complex variants is not found.
CC       Interacts with BCL6; leads to a epigenetic repression of specific
CC       target genes. Interacts with CLOCK, BMAL1 and PER2 (By similarity).
CC       Interacts with PPARA; the interaction seems to be modulated by NAD(+)
CC       levels (PubMed:24043310). Interacts with NR1H3 and this interaction is
CC       inhibited in the presence of CCAR2. Interacts with CHEK2. Interacts
CC       with p53/TP53. Exhibits a preferential interaction with sumoylated
CC       CCAR2 over its unmodified form. Interacts with PACS2 (PubMed:29656858).
CC       Interacts with SIRT7 (By similarity). Interacts with PUS7
CC       (PubMed:31451225). Interacts with TULP3 (PubMed:35397207). Interacts
CC       with MORN3; the interaction enhances the ubiquitination of p53/TP53
CC       (PubMed:29681526). {ECO:0000250|UniProtKB:Q923E4,
CC       ECO:0000269|PubMed:12006491, ECO:0000269|PubMed:12535671,
CC       ECO:0000269|PubMed:15684044, ECO:0000269|PubMed:15692560,
CC       ECO:0000269|PubMed:16166628, ECO:0000269|PubMed:16892051,
CC       ECO:0000269|PubMed:17680780, ECO:0000269|PubMed:17964266,
CC       ECO:0000269|PubMed:18235501, ECO:0000269|PubMed:18235502,
CC       ECO:0000269|PubMed:18485871, ECO:0000269|PubMed:19356714,
CC       ECO:0000269|PubMed:19690166, ECO:0000269|PubMed:20042607,
CC       ECO:0000269|PubMed:20169165, ECO:0000269|PubMed:20375098,
CC       ECO:0000269|PubMed:20955178, ECO:0000269|PubMed:20975832,
CC       ECO:0000269|PubMed:21245319, ECO:0000269|PubMed:21698133,
CC       ECO:0000269|PubMed:21909281, ECO:0000269|PubMed:21933665,
CC       ECO:0000269|PubMed:23352644, ECO:0000269|PubMed:24043310,
CC       ECO:0000269|PubMed:25361978, ECO:0000269|PubMed:25406032,
CC       ECO:0000269|PubMed:25661920, ECO:0000269|PubMed:29656858,
CC       ECO:0000269|PubMed:29681526, ECO:0000269|PubMed:31451225,
CC       ECO:0000269|PubMed:35397207}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HIV-1 Tat.
CC       {ECO:0000269|PubMed:15719057, ECO:0000269|PubMed:18329615}.
CC   -!- INTERACTION:
CC       Q96EB6; Q13085: ACACA; NbExp=3; IntAct=EBI-1802965, EBI-717681;
CC       Q96EB6; P31749: AKT1; NbExp=5; IntAct=EBI-1802965, EBI-296087;
CC       Q96EB6; P27695: APEX1; NbExp=6; IntAct=EBI-1802965, EBI-1048805;
CC       Q96EB6; O95352: ATG7; NbExp=3; IntAct=EBI-1802965, EBI-987834;
CC       Q96EB6; Q8N163: CCAR2; NbExp=16; IntAct=EBI-1802965, EBI-355410;
CC       Q96EB6; P33076: CIITA; NbExp=4; IntAct=EBI-1802965, EBI-1538819;
CC       Q96EB6; Q9NS37: CREBZF; NbExp=3; IntAct=EBI-1802965, EBI-632965;
CC       Q96EB6; Q9Y5P2: CSAG3; NbExp=8; IntAct=EBI-1802965, EBI-26354757;
CC       Q96EB6; P68400: CSNK2A1; NbExp=5; IntAct=EBI-1802965, EBI-347804;
CC       Q96EB6; P67870: CSNK2B; NbExp=5; IntAct=EBI-1802965, EBI-348169;
CC       Q96EB6; P26358: DNMT1; NbExp=11; IntAct=EBI-1802965, EBI-719459;
CC       Q96EB6; O14640: DVL1; NbExp=2; IntAct=EBI-1802965, EBI-723489;
CC       Q96EB6; Q92997: DVL3; NbExp=3; IntAct=EBI-1802965, EBI-739789;
CC       Q96EB6; Q01094: E2F1; NbExp=3; IntAct=EBI-1802965, EBI-448924;
CC       Q96EB6; Q09472: EP300; NbExp=4; IntAct=EBI-1802965, EBI-447295;
CC       Q96EB6; Q14192: FHL2; NbExp=2; IntAct=EBI-1802965, EBI-701903;
CC       Q96EB6; Q12778: FOXO1; NbExp=4; IntAct=EBI-1802965, EBI-1108782;
CC       Q96EB6; O43524: FOXO3; NbExp=5; IntAct=EBI-1802965, EBI-1644164;
CC       Q96EB6; P98177: FOXO4; NbExp=3; IntAct=EBI-1802965, EBI-4481939;
CC       Q96EB6; P51610: HCFC1; NbExp=2; IntAct=EBI-1802965, EBI-396176;
CC       Q96EB6; Q14469: HES1; NbExp=4; IntAct=EBI-1802965, EBI-2832522;
CC       Q96EB6; Q9UBP5: HEY2; NbExp=3; IntAct=EBI-1802965, EBI-750630;
CC       Q96EB6; P09067: HOXB5; NbExp=3; IntAct=EBI-1802965, EBI-3893317;
CC       Q96EB6; Q9Y4H2: IRS2; NbExp=2; IntAct=EBI-1802965, EBI-1049582;
CC       Q96EB6; Q92831: KAT2B; NbExp=3; IntAct=EBI-1802965, EBI-477430;
CC       Q96EB6; Q03164: KMT2A; NbExp=5; IntAct=EBI-1802965, EBI-591370;
CC       Q96EB6; Q9GZQ8: MAP1LC3B; NbExp=2; IntAct=EBI-1802965, EBI-373144;
CC       Q96EB6; Q03112: MECOM; NbExp=2; IntAct=EBI-1802965, EBI-1384862;
CC       Q96EB6; P42345: MTOR; NbExp=2; IntAct=EBI-1802965, EBI-359260;
CC       Q96EB6; P01106: MYC; NbExp=4; IntAct=EBI-1802965, EBI-447544;
CC       Q96EB6; P04198: MYCN; NbExp=3; IntAct=EBI-1802965, EBI-878369;
CC       Q96EB6; O60934: NBN; NbExp=5; IntAct=EBI-1802965, EBI-494844;
CC       Q96EB6; Q02577: NHLH2; NbExp=2; IntAct=EBI-1802965, EBI-5378683;
CC       Q96EB6; Q9HAN9: NMNAT1; NbExp=3; IntAct=EBI-1802965, EBI-3917542;
CC       Q96EB6; Q15466: NR0B2; NbExp=6; IntAct=EBI-1802965, EBI-3910729;
CC       Q96EB6; P27986: PIK3R1; NbExp=3; IntAct=EBI-1802965, EBI-79464;
CC       Q96EB6; P37231: PPARG; NbExp=5; IntAct=EBI-1802965, EBI-781384;
CC       Q96EB6; P10276: RARA; NbExp=3; IntAct=EBI-1802965, EBI-413374;
CC       Q96EB6; Q04206: RELA; NbExp=5; IntAct=EBI-1802965, EBI-73886;
CC       Q96EB6; Q86WX3: RPS19BP1; NbExp=11; IntAct=EBI-1802965, EBI-4479407;
CC       Q96EB6; Q8N122: RPTOR; NbExp=3; IntAct=EBI-1802965, EBI-1567928;
CC       Q96EB6; O43159: RRP8; NbExp=3; IntAct=EBI-1802965, EBI-2008793;
CC       Q96EB6; Q8WTS6: SETD7; NbExp=11; IntAct=EBI-1802965, EBI-1268586;
CC       Q96EB6; Q13573: SNW1; NbExp=7; IntAct=EBI-1802965, EBI-632715;
CC       Q96EB6; P36956-3: SREBF1; NbExp=2; IntAct=EBI-1802965, EBI-948338;
CC       Q96EB6; O43463: SUV39H1; NbExp=5; IntAct=EBI-1802965, EBI-349968;
CC       Q96EB6; Q04724: TLE1; NbExp=4; IntAct=EBI-1802965, EBI-711424;
CC       Q96EB6; P04637: TP53; NbExp=18; IntAct=EBI-1802965, EBI-366083;
CC       Q96EB6; O15350: TP73; NbExp=4; IntAct=EBI-1802965, EBI-389606;
CC       Q96EB6; P49815: TSC2; NbExp=2; IntAct=EBI-1802965, EBI-396587;
CC       Q96EB6; Q14191: WRN; NbExp=9; IntAct=EBI-1802965, EBI-368417;
CC       Q96EB6; P23025: XPA; NbExp=8; IntAct=EBI-1802965, EBI-295222;
CC       Q96EB6; P12956: XRCC6; NbExp=7; IntAct=EBI-1802965, EBI-353208;
CC       Q96EB6; Q8NAP3: ZBTB38; NbExp=3; IntAct=EBI-1802965, EBI-5235984;
CC       Q96EB6; P52744: ZNF138; NbExp=2; IntAct=EBI-1802965, EBI-10746567;
CC       Q96EB6; Q6ZN11: ZNF793; NbExp=2; IntAct=EBI-1802965, EBI-5667494;
CC       Q96EB6; Q9R1E0: Foxo1; Xeno; NbExp=2; IntAct=EBI-1802965, EBI-1371343;
CC       Q96EB6; Q60974: Ncor1; Xeno; NbExp=2; IntAct=EBI-1802965, EBI-349004;
CC       Q96EB6; Q60644: Nr1h2; Xeno; NbExp=2; IntAct=EBI-1802965, EBI-5276809;
CC       Q96EB6; Q9Z0Y9: Nr1h3; Xeno; NbExp=2; IntAct=EBI-1802965, EBI-5276764;
CC       Q96EB6; P37238: Pparg; Xeno; NbExp=3; IntAct=EBI-1802965, EBI-5260705;
CC       Q96EB6; P37238-1: Pparg; Xeno; NbExp=2; IntAct=EBI-1802965, EBI-6267861;
CC       Q96EB6; P04608: tat; Xeno; NbExp=3; IntAct=EBI-1802965, EBI-6164389;
CC   -!- SUBCELLULAR LOCATION: Nucleus, PML body {ECO:0000269|PubMed:12006491}.
CC       Cytoplasm {ECO:0000269|PubMed:20027304}. Nucleus
CC       {ECO:0000269|PubMed:11672523, ECO:0000269|PubMed:15469825,
CC       ECO:0000269|PubMed:16079181, ECO:0000269|PubMed:19934257,
CC       ECO:0000269|PubMed:20027304, ECO:0000269|PubMed:20167603,
CC       ECO:0000269|PubMed:20955178}. Note=Recruited to the nuclear bodies via
CC       its interaction with PML (PubMed:12006491). Colocalized with APEX1 in
CC       the nucleus (PubMed:19934257). May be found in nucleolus, nuclear
CC       euchromatin, heterochromatin and inner membrane (PubMed:15469825).
CC       Shuttles between nucleus and cytoplasm (By similarity). Colocalizes in
CC       the nucleus with XBP1 isoform 2 (PubMed:20955178).
CC       {ECO:0000250|UniProtKB:Q923E4, ECO:0000269|PubMed:12006491,
CC       ECO:0000269|PubMed:15469825, ECO:0000269|PubMed:19934257,
CC       ECO:0000269|PubMed:20955178}.
CC   -!- SUBCELLULAR LOCATION: [SirtT1 75 kDa fragment]: Cytoplasm
CC       {ECO:0000269|PubMed:21987377}. Mitochondrion
CC       {ECO:0000269|PubMed:21987377}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q96EB6-1; Sequence=Displayed;
CC       Name=2; Synonyms=delta-exon8;
CC         IsoId=Q96EB6-2; Sequence=VSP_042189;
CC   -!- TISSUE SPECIFICITY: Widely expressed. {ECO:0000269|PubMed:10381378}.
CC   -!- INDUCTION: Up-regulated by methyl methanesulfonate (MMS). In H293T
CC       cells by presence of rat calorie restriction (CR) serum.
CC       {ECO:0000269|PubMed:15205477, ECO:0000269|PubMed:19934257}.
CC   -!- PTM: Methylated on multiple lysine residues; methylation is enhanced
CC       after DNA damage and is dispensable for deacetylase activity toward
CC       p53/TP53. {ECO:0000269|PubMed:21245319}.
CC   -!- PTM: Phosphorylated. Phosphorylated by STK4/MST1, resulting in
CC       inhibition of SIRT1-mediated p53/TP53 deacetylation. Phosphorylation by
CC       MAPK8/JNK1 at Ser-27, Ser-47, and Thr-530 leads to increased nuclear
CC       localization and enzymatic activity. Phosphorylation at Thr-530 by
CC       DYRK1A and DYRK3 activates deacetylase activity and promotes cell
CC       survival. Phosphorylation by mammalian target of rapamycin complex 1
CC       (mTORC1) at Ser-47 inhibits deacetylation activity. Phosphorylated by
CC       CaMK2, leading to increased p53/TP53 and NF-kappa-B p65/RELA
CC       deacetylation activity (By similarity). Phosphorylation at Ser-27
CC       implicating MAPK9 is linked to protein stability. There is some
CC       ambiguity for some phosphosites: Ser-159/Ser-162 and Thr-544/Ser-545.
CC       {ECO:0000250|UniProtKB:Q923E4, ECO:0000269|PubMed:18838864,
CC       ECO:0000269|PubMed:19107194, ECO:0000269|PubMed:19236849,
CC       ECO:0000269|PubMed:20027304, ECO:0000269|PubMed:21212262,
CC       ECO:0000269|PubMed:21471201}.
CC   -!- PTM: Proteolytically cleaved by cathepsin B upon TNF-alpha treatment to
CC       yield catalytic inactive but stable SirtT1 75 kDa fragment (75SirT1).
CC       {ECO:0000269|PubMed:21987377}.
CC   -!- PTM: S-nitrosylated by GAPDH, leading to inhibit the NAD-dependent
CC       protein deacetylase activity. {ECO:0000250|UniProtKB:Q923E4}.
CC   -!- PTM: Acetylated at various Lys residues. Deacetylated via an
CC       autocatalytic mechanism. Autodeacetylation at Lys-238 promotes its
CC       protein deacetylase activity. {ECO:0000250|UniProtKB:Q923E4}.
CC   -!- PTM: Ubiquitinated; leading to degradation. Deubiquitinated by USP22;
CC       leading to stabilization. {ECO:0000269|PubMed:22542455}.
CC   -!- MISCELLANEOUS: Red wine, which contains resveratrol, may participate in
CC       activation of sirtuin proteins, and may therefore participate in an
CC       extended lifespan as it has been observed in yeast.
CC   -!- MISCELLANEOUS: Calf histone H1 is used as substrate in the in vitro
CC       deacetylation assay (PubMed:15469825). As, in vivo, interaction occurs
CC       between SIRT1 with H1-4, deacetylation has been validated only for H1-
CC       4. {ECO:0000305|PubMed:15469825}.
CC   -!- MISCELLANEOUS: The reported ADP-ribosyltransferase activity of sirtuins
CC       is likely some inefficient side reaction of the deacetylase activity
CC       and may not be physiologically relevant. {ECO:0000305|PubMed:19220062}.
CC   -!- SIMILARITY: Belongs to the sirtuin family. Class I subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH12499.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/44006/SIRT1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF083106; AAD40849.2; -; mRNA.
DR   EMBL; AF235040; AAG38486.1; -; mRNA.
DR   EMBL; DQ278604; ABB72675.1; -; Genomic_DNA.
DR   EMBL; AL133551; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC012499; AAH12499.1; ALT_INIT; mRNA.
DR   CCDS; CCDS7273.1; -. [Q96EB6-1]
DR   RefSeq; NP_001135970.1; NM_001142498.1.
DR   RefSeq; NP_001300978.1; NM_001314049.1.
DR   RefSeq; NP_036370.2; NM_012238.4. [Q96EB6-1]
DR   PDB; 4I5I; X-ray; 2.50 A; A/B=241-516.
DR   PDB; 4IF6; X-ray; 2.25 A; A=234-510, B=641-665.
DR   PDB; 4IG9; X-ray; 2.64 A; A/C/E/G=234-510, B/D/F/H=641-665.
DR   PDB; 4KXQ; X-ray; 1.85 A; A=234-510, B=641-663.
DR   PDB; 4ZZH; X-ray; 3.10 A; A=183-505.
DR   PDB; 4ZZI; X-ray; 2.73 A; A=183-505.
DR   PDB; 4ZZJ; X-ray; 2.74 A; A=183-505.
DR   PDB; 5BTR; X-ray; 3.20 A; A/B/C=143-665.
DR   PDB; 8ANB; X-ray; 1.64 A; P=665-675.
DR   PDBsum; 4I5I; -.
DR   PDBsum; 4IF6; -.
DR   PDBsum; 4IG9; -.
DR   PDBsum; 4KXQ; -.
DR   PDBsum; 4ZZH; -.
DR   PDBsum; 4ZZI; -.
DR   PDBsum; 4ZZJ; -.
DR   PDBsum; 5BTR; -.
DR   PDBsum; 8ANB; -.
DR   AlphaFoldDB; Q96EB6; -.
DR   SMR; Q96EB6; -.
DR   BioGRID; 116983; 410.
DR   ComplexPortal; CPX-467; eNoSc complex.
DR   CORUM; Q96EB6; -.
DR   DIP; DIP-29757N; -.
DR   FunCoup; Q96EB6; 4620.
DR   IntAct; Q96EB6; 243.
DR   MINT; Q96EB6; -.
DR   STRING; 9606.ENSP00000212015; -.
DR   BindingDB; Q96EB6; -.
DR   ChEMBL; CHEMBL4506; -.
DR   DrugBank; DB15493; Cambinol.
DR   DrugBank; DB02709; Resveratrol.
DR   DrugBank; DB13978; Selisistat.
DR   DrugBank; DB12186; SRT-2104.
DR   DrugCentral; Q96EB6; -.
DR   GuidetoPHARMACOLOGY; 2707; -.
DR   MoonProt; Q96EB6; -.
DR   GlyCosmos; Q96EB6; 2 sites, 1 glycan.
DR   GlyGen; Q96EB6; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; Q96EB6; -.
DR   MetOSite; Q96EB6; -.
DR   PhosphoSitePlus; Q96EB6; -.
DR   BioMuta; SIRT1; -.
DR   DMDM; 38258633; -.
DR   jPOST; Q96EB6; -.
DR   MassIVE; Q96EB6; -.
DR   PaxDb; 9606-ENSP00000212015; -.
DR   PeptideAtlas; Q96EB6; -.
DR   ProteomicsDB; 76393; -. [Q96EB6-1]
DR   ProteomicsDB; 76394; -. [Q96EB6-2]
DR   Pumba; Q96EB6; -.
DR   Antibodypedia; 1637; 1151 antibodies from 51 providers.
DR   DNASU; 23411; -.
DR   Ensembl; ENST00000212015.11; ENSP00000212015.6; ENSG00000096717.12. [Q96EB6-1]
DR   GeneID; 23411; -.
DR   KEGG; hsa:23411; -.
DR   MANE-Select; ENST00000212015.11; ENSP00000212015.6; NM_012238.5; NP_036370.2.
DR   UCSC; uc001jnd.3; human. [Q96EB6-1]
DR   AGR; HGNC:14929; -.
DR   CTD; 23411; -.
DR   DisGeNET; 23411; -.
DR   GeneCards; SIRT1; -.
DR   HGNC; HGNC:14929; SIRT1.
DR   HPA; ENSG00000096717; Low tissue specificity.
DR   MalaCards; SIRT1; -.
DR   MIM; 604479; gene.
DR   OpenTargets; ENSG00000096717; -.
DR   VEuPathDB; HostDB:ENSG00000096717; -.
DR   eggNOG; KOG2684; Eukaryota.
DR   GeneTree; ENSGT00940000159406; -.
DR   HOGENOM; CLU_016587_0_0_1; -.
DR   InParanoid; Q96EB6; -.
DR   OMA; RYWMSRV; -.
DR   OrthoDB; 424302at2759; -.
DR   PAN-GO; Q96EB6; 10 GO annotations based on evolutionary models.
DR   PhylomeDB; Q96EB6; -.
DR   BioCyc; MetaCyc:ENSG00000096717-MONOMER; -.
DR   BRENDA; 2.3.1.286; 2681.
DR   PathwayCommons; Q96EB6; -.
DR   Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response.
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   Reactome; R-HSA-427359; SIRT1 negatively regulates rRNA expression.
DR   Reactome; R-HSA-9617629; Regulation of FOXO transcriptional activity by acetylation.
DR   Reactome; R-HSA-9707616; Heme signaling.
DR   Reactome; R-HSA-9841922; MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis.
DR   Reactome; R-HSA-9854907; Regulation of MITF-M dependent genes involved in metabolism.
DR   Reactome; R-HSA-9856649; Transcriptional and post-translational regulation of MITF-M expression and activity.
DR   SABIO-RK; Q96EB6; -.
DR   SignaLink; Q96EB6; -.
DR   SIGNOR; Q96EB6; -.
DR   STRENDA-DB; NC2FY0; SIRT1 WT and variant activation by resveratrol and STAC1.
DR   BioGRID-ORCS; 23411; 25 hits in 1175 CRISPR screens.
DR   CD-CODE; B5B9A610; PML body.
DR   EvolutionaryTrace; Q96EB6; -.
DR   GeneWiki; Sirtuin_1; -.
DR   GenomeRNAi; 23411; -.
DR   Pharos; Q96EB6; Tchem.
DR   PRO; PR:Q96EB6; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; Q96EB6; protein.
DR   Bgee; ENSG00000096717; Expressed in calcaneal tendon and 192 other cell types or tissues.
DR   ExpressionAtlas; Q96EB6; baseline and differential.
DR   GO; GO:0000785; C:chromatin; IDA:UniProtKB.
DR   GO; GO:0005677; C:chromatin silencing complex; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0061773; C:eNoSc complex; IPI:ComplexPortal.
DR   GO; GO:0000791; C:euchromatin; IDA:UniProtKB.
DR   GO; GO:0001650; C:fibrillar center; IDA:HPA.
DR   GO; GO:0000792; C:heterochromatin; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0005635; C:nuclear envelope; IDA:BHF-UCL.
DR   GO; GO:0005637; C:nuclear inner membrane; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IDA:BHF-UCL.
DR   GO; GO:0033553; C:rDNA heterochromatin; IDA:UniProtKB.
DR   GO; GO:0043425; F:bHLH transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0019213; F:deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0008047; F:enzyme activator activity; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0042393; F:histone binding; IPI:UniProtKB.
DR   GO; GO:0004407; F:histone deacetylase activity; EXP:Reactome.
DR   GO; GO:0017136; F:histone deacetylase activity, NAD-dependent; IDA:UniProtKB.
DR   GO; GO:0141050; F:histone H3K deacetylase activity; IDA:BHF-UCL.
DR   GO; GO:0032041; F:histone H3K14 deacetylase activity, NAD-dependent; IDA:BHF-UCL.
DR   GO; GO:0046969; F:histone H3K9 deacetylase activity, NAD-dependent; IDA:BHF-UCL.
DR   GO; GO:0140937; F:histone H4K12 deacetylase activity, hydrolytic mechanism; IDA:BHF-UCL.
DR   GO; GO:0046970; F:histone H4K16 deacetylase activity, NAD-dependent; IDA:BHF-UCL.
DR   GO; GO:0043398; F:HLH domain binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:BHF-UCL.
DR   GO; GO:1990254; F:keratin filament binding; IPI:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0051019; F:mitogen-activated protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0070403; F:NAD+ binding; IBA:GO_Central.
DR   GO; GO:0160012; F:NAD-dependent histone decrotonylase activity; IDA:UniProtKB.
DR   GO; GO:0034979; F:NAD-dependent protein lysine deacetylase activity; IDA:UniProt.
DR   GO; GO:0141208; F:NAD-dependent protein lysine delactylase activity; IDA:UniProtKB.
DR   GO; GO:0106231; F:NAD-dependent protein-lysine depropionylase activity; ISS:UniProtKB.
DR   GO; GO:0016922; F:nuclear receptor binding; IPI:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IPI:BHF-UCL.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; IEA:Ensembl.
DR   GO; GO:0033558; F:protein lysine deacetylase activity; IDA:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0003713; F:transcription coactivator activity; IEA:Ensembl.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:BHF-UCL.
DR   GO; GO:0140416; F:transcription regulator inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0001525; P:angiogenesis; IDA:UniProtKB.
DR   GO; GO:0042595; P:behavioral response to starvation; IEA:Ensembl.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IMP:ComplexPortal.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IDA:BHF-UCL.
DR   GO; GO:0071456; P:cellular response to hypoxia; IMP:UniProtKB.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; ISS:UniProtKB.
DR   GO; GO:1990830; P:cellular response to leukemia inhibitory factor; IEA:Ensembl.
DR   GO; GO:0009267; P:cellular response to starvation; ISS:BHF-UCL.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB.
DR   GO; GO:0042632; P:cholesterol homeostasis; ISS:UniProtKB.
DR   GO; GO:0006325; P:chromatin organization; IMP:UniProtKB.
DR   GO; GO:0032922; P:circadian regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0006974; P:DNA damage response; IDA:UniProtKB.
DR   GO; GO:0006346; P:DNA methylation-dependent constitutive heterochromatin formation; TAS:UniProtKB.
DR   GO; GO:0140861; P:DNA repair-dependent chromatin remodeling; IDA:UniProt.
DR   GO; GO:0000731; P:DNA synthesis involved in DNA repair; ISS:UniProtKB.
DR   GO; GO:0097009; P:energy homeostasis; IMP:ComplexPortal.
DR   GO; GO:0055089; P:fatty acid homeostasis; ISS:UniProtKB.
DR   GO; GO:0031507; P:heterochromatin formation; IDA:BHF-UCL.
DR   GO; GO:0001678; P:intracellular glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0035356; P:intracellular triglyceride homeostasis; ISS:UniProtKB.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IMP:UniProtKB.
DR   GO; GO:0033210; P:leptin-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0030225; P:macrophage differentiation; ISS:UniProtKB.
DR   GO; GO:0051658; P:maintenance of nucleus location; IDA:UniProt.
DR   GO; GO:0007517; P:muscle organ development; IEA:UniProtKB-KW.
DR   GO; GO:0060766; P:negative regulation of androgen receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:1902424; P:negative regulation of attachment of mitotic spindle microtubules to kinetochore; IDA:UniProt.
DR   GO; GO:0043124; P:negative regulation of canonical NF-kappaB signal transduction; IDA:UniProtKB.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IMP:ComplexPortal.
DR   GO; GO:2000655; P:negative regulation of cellular response to testosterone stimulus; IMP:BHF-UCL.
DR   GO; GO:2000773; P:negative regulation of cellular senescence; IDA:UniProtKB.
DR   GO; GO:0043518; P:negative regulation of DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL.
DR   GO; GO:0043433; P:negative regulation of DNA-binding transcription factor activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:CACAO.
DR   GO; GO:0035331; P:negative regulation of hippo signaling; IDA:UniProt.
DR   GO; GO:1902166; P:negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; ISS:BHF-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:1902176; P:negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:2000757; P:negative regulation of peptidyl-lysine acetylation; IDA:UniProtKB.
DR   GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:UniProtKB.
DR   GO; GO:0042326; P:negative regulation of phosphorylation; IMP:UniProtKB.
DR   GO; GO:0031393; P:negative regulation of prostaglandin biosynthetic process; ISS:UniProtKB.
DR   GO; GO:1901984; P:negative regulation of protein acetylation; IMP:CACAO.
DR   GO; GO:1901797; P:negative regulation of signal transduction by p53 class mediator; IDA:UniProt.
DR   GO; GO:0032007; P:negative regulation of TOR signaling; IMP:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0010868; P:negative regulation of triglyceride biosynthetic process; IDA:UniProt.
DR   GO; GO:0001542; P:ovulation from ovarian follicle; IEA:Ensembl.
DR   GO; GO:0018394; P:peptidyl-lysine acetylation; IMP:UniProtKB.
DR   GO; GO:0002821; P:positive regulation of adaptive immune response; IDA:UniProtKB.
DR   GO; GO:1904179; P:positive regulation of adipose tissue development; ISS:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IDA:BHF-UCL.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:2000481; P:positive regulation of cAMP-dependent protein kinase activity; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:2000774; P:positive regulation of cellular senescence; IDA:UniProtKB.
DR   GO; GO:0010875; P:positive regulation of cholesterol efflux; ISS:UniProtKB.
DR   GO; GO:0045739; P:positive regulation of DNA repair; IMP:UniProtKB.
DR   GO; GO:2000781; P:positive regulation of double-strand break repair; IDA:UniProt.
DR   GO; GO:1902237; P:positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:AgBase.
DR   GO; GO:0045722; P:positive regulation of gluconeogenesis; IDA:UniProtKB.
DR   GO; GO:0046628; P:positive regulation of insulin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; IDA:UniProtKB.
DR   GO; GO:2000111; P:positive regulation of macrophage apoptotic process; ISS:UniProtKB.
DR   GO; GO:0060907; P:positive regulation of macrophage cytokine production; ISS:UniProtKB.
DR   GO; GO:0045348; P:positive regulation of MHC class II biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISS:UniProtKB.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IMP:AgBase.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0051152; P:positive regulation of smooth muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0006476; P:protein deacetylation; IDA:UniProtKB.
DR   GO; GO:0106230; P:protein depropionylation; ISS:UniProtKB.
DR   GO; GO:0031648; P:protein destabilization; ISS:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0000720; P:pyrimidine dimer repair by nucleotide-excision repair; IMP:UniProtKB.
DR   GO; GO:0000183; P:rDNA heterochromatin formation; IDA:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0070857; P:regulation of bile acid biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0090335; P:regulation of brown fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IMP:BHF-UCL.
DR   GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome.
DR   GO; GO:0010824; P:regulation of centrosome duplication; IDA:UniProtKB.
DR   GO; GO:0032071; P:regulation of endodeoxyribonuclease activity; IMP:UniProtKB.
DR   GO; GO:0010906; P:regulation of glucose metabolic process; ISS:UniProtKB.
DR   GO; GO:0010883; P:regulation of lipid storage; ISS:UniProtKB.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IDA:UniProtKB.
DR   GO; GO:0035358; P:regulation of peroxisome proliferator activated receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0034391; P:regulation of smooth muscle cell apoptotic process; ISS:UniProtKB.
DR   GO; GO:0046015; P:regulation of transcription by glucose; IMP:ComplexPortal.
DR   GO; GO:0042542; P:response to hydrogen peroxide; IDA:UniProtKB.
DR   GO; GO:0032868; P:response to insulin; ISS:UniProtKB.
DR   GO; GO:0044321; P:response to leptin; ISS:UniProtKB.
DR   GO; GO:0006979; P:response to oxidative stress; IDA:UniProtKB.
DR   GO; GO:0000012; P:single strand break repair; IMP:UniProtKB.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0090400; P:stress-induced premature senescence; IMP:CACAO.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0006642; P:triglyceride mobilization; ISS:BHF-UCL.
DR   GO; GO:0070914; P:UV-damage excision repair; IMP:CACAO.
DR   GO; GO:0050872; P:white fat cell differentiation; ISS:BHF-UCL.
DR   CDD; cd01408; SIRT1; 1.
DR   FunFam; 3.30.1600.10:FF:000013; NAD-dependent protein deacetylase sirtuin-1; 2.
DR   Gene3D; 3.30.1600.10; SIR2/SIRT2 'Small Domain; 1.
DR   Gene3D; 3.40.50.1220; TPP-binding domain; 1.
DR   InterPro; IPR029035; DHS-like_NAD/FAD-binding_dom.
DR   InterPro; IPR050134; NAD-dep_sirtuin_deacylases.
DR   InterPro; IPR003000; Sirtuin.
DR   InterPro; IPR026591; Sirtuin_cat_small_dom_sf.
DR   InterPro; IPR026590; Ssirtuin_cat_dom.
DR   PANTHER; PTHR11085:SF9; NAD-DEPENDENT PROTEIN DEACETYLASE SIRTUIN-1; 1.
DR   PANTHER; PTHR11085; NAD-DEPENDENT PROTEIN DEACYLASE SIRTUIN-5, MITOCHONDRIAL-RELATED; 1.
DR   Pfam; PF02146; SIR2; 1.
DR   SUPFAM; SSF52467; DHS-like NAD/FAD-binding domain; 1.
DR   PROSITE; PS50305; SIRTUIN; 1.
DR   neXtProt; NX_Q96EB6; -.
DR   PharmGKB; PA37935; -.
DR   TreeFam; TF105896; -.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis;
KW   Biological rhythms; Cytoplasm; Developmental protein; Differentiation;
KW   Host-virus interaction; Metal-binding; Methylation; Mitochondrion;
KW   Myogenesis; NAD; Nucleus; Phosphoprotein; Proteomics identification;
KW   Reference proteome; S-nitrosylation; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation; Zinc.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:22223895, ECO:0007744|PubMed:22814378"
FT   CHAIN           2..747
FT                   /note="NAD-dependent protein deacetylase sirtuin-1"
FT                   /id="PRO_0000110256"
FT   CHAIN           2..533
FT                   /note="SirtT1 75 kDa fragment"
FT                   /id="PRO_0000415289"
FT   DOMAIN          236..496
FT                   /note="Deacetylase sirtuin-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00236"
FT   REGION          1..135
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2..268
FT                   /note="Interaction with H1-4"
FT                   /evidence="ECO:0000269|PubMed:15469825"
FT   REGION          2..139
FT                   /note="Interaction with CLOCK"
FT                   /evidence="ECO:0000250|UniProtKB:Q923E4"
FT   REGION          143..541
FT                   /note="Interaction with CCAR2"
FT   REGION          256..259
FT                   /note="Required for interaction with the sumoylated form of
FT                   CCAR2"
FT                   /evidence="ECO:0000269|PubMed:25406032"
FT   REGION          523..549
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          538..540
FT                   /note="Phosphorylated at one of three serine residues"
FT   REGION          562..587
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          663..726
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           32..39
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000250"
FT   MOTIF           138..145
FT                   /note="Nuclear export signal"
FT                   /evidence="ECO:0000250"
FT   MOTIF           223..230
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000250"
FT   MOTIF           425..431
FT                   /note="Nuclear export signal"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        61..100
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        120..135
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        537..549
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        569..580
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        666..677
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        687..707
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        363
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00236,
FT                   ECO:0000269|PubMed:11672523, ECO:0000269|PubMed:12006491,
FT                   ECO:0000269|PubMed:12535671, ECO:0000269|PubMed:17290224,
FT                   ECO:0000269|PubMed:18004385, ECO:0000269|PubMed:18235501,
FT                   ECO:0000269|PubMed:18485871, ECO:0000269|PubMed:19934257,
FT                   ECO:0000269|PubMed:25406032, ECO:0000269|PubMed:28497810,
FT                   ECO:0000269|PubMed:38512451"
FT   BINDING         261..280
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000250|UniProtKB:Q8IXJ6"
FT   BINDING         345..348
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000250|UniProtKB:Q8IXJ6"
FT   BINDING         371
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00236"
FT   BINDING         374
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00236"
FT   BINDING         395
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00236"
FT   BINDING         398
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00236"
FT   BINDING         440..442
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000250|UniProtKB:Q8IXJ6"
FT   BINDING         465..467
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000250|UniProtKB:Q8IXJ6"
FT   BINDING         482
FT                   /ligand="NAD(+)"
FT                   /ligand_id="ChEBI:CHEBI:57540"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:22223895, ECO:0007744|PubMed:22814378"
FT   MOD_RES         14
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:19107194,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         26
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:19107194"
FT   MOD_RES         27
FT                   /note="Phosphoserine; by MAPK8"
FT                   /evidence="ECO:0000269|PubMed:18838864,
FT                   ECO:0000269|PubMed:19107194, ECO:0000269|PubMed:20027304,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         47
FT                   /note="Phosphoserine; by MAPK8"
FT                   /evidence="ECO:0000269|PubMed:18838864,
FT                   ECO:0000269|PubMed:19107194, ECO:0000269|PubMed:20027304,
FT                   ECO:0000269|PubMed:21471201, ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         159
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:19107194"
FT   MOD_RES         162
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:19107194"
FT   MOD_RES         172
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:19107194"
FT   MOD_RES         173
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:19107194"
FT   MOD_RES         238
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q923E4"
FT   MOD_RES         377
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q923E4"
FT   MOD_RES         395
FT                   /note="S-nitrosocysteine"
FT                   /evidence="ECO:0000250|UniProtKB:Q923E4"
FT   MOD_RES         398
FT                   /note="S-nitrosocysteine"
FT                   /evidence="ECO:0000250|UniProtKB:Q923E4"
FT   MOD_RES         430
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q923E4"
FT   MOD_RES         513
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q923E4"
FT   MOD_RES         530
FT                   /note="Phosphothreonine; by DYRK1A, DYRK3 and MAPK8"
FT                   /evidence="ECO:0000269|PubMed:19107194,
FT                   ECO:0000269|PubMed:20027304, ECO:0007744|PubMed:19690332"
FT   MOD_RES         535
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         544
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000305|PubMed:19107194"
FT   MOD_RES         545
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:19107194"
FT   MOD_RES         610
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q923E4"
FT   MOD_RES         659
FT                   /note="Phosphoserine; by CaMK2"
FT                   /evidence="ECO:0000250|UniProtKB:Q923E4"
FT   MOD_RES         661
FT                   /note="Phosphoserine; by CaMK2"
FT                   /evidence="ECO:0000305|PubMed:19236849"
FT   MOD_RES         719
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:19107194,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         747
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:19107194"
FT   VAR_SEQ         454..639
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_042189"
FT   VARIANT         3
FT                   /note="D -> E (in dbSNP:rs35671182)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_025148"
FT   VARIANT         484
FT                   /note="V -> D (in dbSNP:rs1063111)"
FT                   /id="VAR_051976"
FT   MUTAGEN         27
FT                   /note="S->A: Greatly diminishes phosphorylation by MAPK8;
FT                   when associated with A-47 and A-530."
FT                   /evidence="ECO:0000269|PubMed:20027304"
FT   MUTAGEN         47
FT                   /note="S->A: Blocks residue phosphorylation, restores
FT                   deacetylation activity and inhibits DNA damage-induced
FT                   apoptosis."
FT                   /evidence="ECO:0000269|PubMed:20027304,
FT                   ECO:0000269|PubMed:21471201"
FT   MUTAGEN         47
FT                   /note="S->A: Greatly diminishes phosphorylation by MAPK8;
FT                   when associated with A-27 and A-530."
FT                   /evidence="ECO:0000269|PubMed:20027304,
FT                   ECO:0000269|PubMed:21471201"
FT   MUTAGEN         233
FT                   /note="K->R: Impairs in vitro methylation by SETD7; when
FT                   associated with R-235, R-236 and R-238."
FT                   /evidence="ECO:0000269|PubMed:21245319"
FT   MUTAGEN         235
FT                   /note="K->R: Impairs in vitro methylation by SETD7; when
FT                   associated with R-233, R-236 and R-238."
FT                   /evidence="ECO:0000269|PubMed:21245319"
FT   MUTAGEN         236
FT                   /note="K->R: Impairs in vitro methylation by SETD7; when
FT                   associated with R-233, R-235 and R-238."
FT                   /evidence="ECO:0000269|PubMed:21245319"
FT   MUTAGEN         238
FT                   /note="K->R: Impairs in vitro methylation by SETD7; when
FT                   associated with R-233, R-235a and R-236."
FT                   /evidence="ECO:0000269|PubMed:21245319"
FT   MUTAGEN         256..257
FT                   /note="II->KK: Loss of interaction with the sumoylated form
FT                   of CCAR2. No effect on its deacetylation activity."
FT                   /evidence="ECO:0000269|PubMed:25406032"
FT   MUTAGEN         363
FT                   /note="H->Y: Loss of function; abolishes both protein
FT                   deacetylase, delactylase and decrotonylase activities.
FT                   Reduces the interaction with CCAR2 and APEX1. Increases
FT                   acetylation of APEX1."
FT                   /evidence="ECO:0000269|PubMed:11672523,
FT                   ECO:0000269|PubMed:12006491, ECO:0000269|PubMed:12535671,
FT                   ECO:0000269|PubMed:17290224, ECO:0000269|PubMed:18004385,
FT                   ECO:0000269|PubMed:18235501, ECO:0000269|PubMed:18485871,
FT                   ECO:0000269|PubMed:19934257, ECO:0000269|PubMed:25406032,
FT                   ECO:0000269|PubMed:28497810, ECO:0000269|PubMed:32034146,
FT                   ECO:0000269|PubMed:32538779, ECO:0000269|PubMed:38512451"
FT   MUTAGEN         474
FT                   /note="F->A: Abolishes phosphorylation at Ser-47, restores
FT                   deacetylation activity and inhibits DNA damage-induced
FT                   apoptosis."
FT                   /evidence="ECO:0000269|PubMed:21471201"
FT   MUTAGEN         530
FT                   /note="T->A: Greatly diminishes phosphorylation by MAPK8;
FT                   when associated with A-27 and A-47."
FT                   /evidence="ECO:0000269|PubMed:19107194,
FT                   ECO:0000269|PubMed:20027304"
FT   MUTAGEN         530
FT                   /note="T->A: Reduces in vitro phosphorylation by CDK1.
FT                   Impairs cell proliferation and cell cycle progression; when
FT                   associated with A-540."
FT                   /evidence="ECO:0000269|PubMed:19107194,
FT                   ECO:0000269|PubMed:20027304"
FT   MUTAGEN         540
FT                   /note="S->A: Reduces in vitro phosphorylation by CDK1.
FT                   Impairs cell proliferation and cell cycle progression; when
FT                   associated with A-530."
FT                   /evidence="ECO:0000269|PubMed:19107194"
FT   MUTAGEN         659
FT                   /note="S->A: Reduces in vitro phosphorylation by CaMK2;
FT                   when associated with S-661. Greatly reduces in vivo
FT                   phosphorylation; when associated with A-661."
FT                   /evidence="ECO:0000269|PubMed:19236849"
FT   MUTAGEN         661
FT                   /note="S->A: Reduces in vitro phosphorylation by CaMK2;
FT                   when associated with S-659. Greatly reduces in vivo
FT                   phosphorylation; when associated with A-659."
FT                   /evidence="ECO:0000269|PubMed:19236849"
FT   MUTAGEN         684
FT                   /note="S->A: No effect on phosphorylation (in vitro and in
FT                   vivo)."
FT                   /evidence="ECO:0000269|PubMed:19236849"
FT   CONFLICT        386..389
FT                   /note="DIFN -> ALFS (in Ref. 5; AAH12499)"
FT                   /evidence="ECO:0000305"
FT   HELIX           184..194
FT                   /evidence="ECO:0007829|PDB:4ZZI"
FT   HELIX           198..205
FT                   /evidence="ECO:0007829|PDB:4ZZI"
FT   HELIX           217..228
FT                   /evidence="ECO:0007829|PDB:4ZZI"
FT   HELIX           243..252
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   STRAND          254..260
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   HELIX           262..268
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   STRAND          273..275
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   TURN            276..278
FT                   /evidence="ECO:0007829|PDB:4IG9"
FT   HELIX           279..286
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   STRAND          290..292
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   HELIX           293..297
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   HELIX           299..304
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   HELIX           307..312
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   HELIX           313..316
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   STRAND          318..320
FT                   /evidence="ECO:0007829|PDB:4I5I"
FT   HELIX           325..335
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   STRAND          339..344
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   HELIX           350..354
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   STRAND          358..361
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   STRAND          364..371
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   TURN            372..374
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   STRAND          377..379
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   HELIX           380..382
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   HELIX           384..388
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   STRAND          396..398
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   STRAND          406..411
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   HELIX           420..429
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   TURN            430..432
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   STRAND          435..440
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   HELIX           448..450
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   HELIX           451..454
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   STRAND          461..467
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   STRAND          475..480
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   HELIX           482..493
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   HELIX           495..500
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   STRAND          506..510
FT                   /evidence="ECO:0007829|PDB:5BTR"
FT   STRAND          643..645
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   TURN            646..648
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   STRAND          649..651
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   HELIX           656..658
FT                   /evidence="ECO:0007829|PDB:4KXQ"
FT   TURN            671..674
FT                   /evidence="ECO:0007829|PDB:8ANB"
SQ   SEQUENCE   747 AA;  81681 MW;  2D3BEA6D73DA229F CRC64;
     MADEAALALQ PGGSPSAAGA DREAASSPAG EPLRKRPRRD GPGLERSPGE PGGAAPEREV
     PAAARGCPGA AAAALWREAE AEAAAAGGEQ EAQATAAAGE GDNGPGLQGP SREPPLADNL
     YDEDDDDEGE EEEEAAAAAI GYRDNLLFGD EIITNGFHSC ESDEEDRASH ASSSDWTPRP
     RIGPYTFVQQ HLMIGTDPRT ILKDLLPETI PPPELDDMTL WQIVINILSE PPKRKKRKDI
     NTIEDAVKLL QECKKIIVLT GAGVSVSCGI PDFRSRDGIY ARLAVDFPDL PDPQAMFDIE
     YFRKDPRPFF KFAKEIYPGQ FQPSLCHKFI ALSDKEGKLL RNYTQNIDTL EQVAGIQRII
     QCHGSFATAS CLICKYKVDC EAVRGDIFNQ VVPRCPRCPA DEPLAIMKPE IVFFGENLPE
     QFHRAMKYDK DEVDLLIVIG SSLKVRPVAL IPSSIPHEVP QILINREPLP HLHFDVELLG
     DCDVIINELC HRLGGEYAKL CCNPVKLSEI TEKPPRTQKE LAYLSELPPT PLHVSEDSSS
     PERTSPPDSS VIVTLLDQAA KSNDDLDVSE SKGCMEEKPQ EVQTSRNVES IAEQMENPDL
     KNVGSSTGEK NERTSVAGTV RKCWPNRVAK EQISRRLDGN QYLFLPPNRY IFHGAEVYSD
     SEDDVLSSSS CGSNSDSGTC QSPSLEEPME DESEIEEFYN GLEDEPDVPE RAGGAGFGTD
     GDDQEAINEA ISVKQEVTDM NYPSNKS
//
